Data / Research funding / Colorectal Cancer
Colorectal Cancer: 698 NIH awards ($1.1B) to 195 organizations
698 NIH awards ($1.1B) in the NIH spending category Colorectal Cancer, to 195 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
The 500 largest of 698 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| Mayo Clinic Comprehensive Cancer Center Support Grant | NIH | National Cancer Institute | 2021 to 2025 | $29,249,641 | April 25, 1997 | August 31, 2030 | WILLMAN, CHERYL LYNN | reporter.nih.gov |
| Environmental triggers of early-onset colorectal cancer: interactions between microplastics and pks+ E coli in early-life gut colonization | NIH | National Cancer Institute | 2021 to 2025 | $22,669,275 | August 1, 1997 | July 31, 2026 | TUVESON, DAVID A | reporter.nih.gov |
| A Follow-up Study for Causes of Cancer in Black Women | NIH | National Cancer Institute | 2021 to 2025 | $11,271,706 | September 21, 2012 | August 31, 2027 | PALMER, JULIE R | reporter.nih.gov |
| Determining the mechanism of pks+ E.coli-associated carcinogenesis in early onset colorectal cancer. | NIH | National Cancer Institute | 2022 to 2025 | $9,558,240 | September 20, 2022 | August 31, 2027 | O'REILLY, EILEEN MARY | reporter.nih.gov |
| Transdisciplinary Team Science in Colorectal Cancer Prognosis: the ColoCare Study | NIH | National Cancer Institute | 2021 to 2025 | $9,251,154 | September 19, 2016 | August 31, 2026 | ULRICH, CORNELIA M | reporter.nih.gov |
| Colon Cancer Family Registry Cohort | NIH | National Cancer Institute | 2021 to 2025 | $8,978,119 | May 1, 2013 | April 30, 2028 | JENKINS, MARK A | reporter.nih.gov |
| Understanding adenoma progression: Interplay among tissue microenvironment, clonal architecture, and gut microbiome | NIH | National Cancer Institute | 2022 to 2025 | $7,696,898 | September 20, 2022 | August 31, 2027 | GRADY, WILLIAM MALLORY | reporter.nih.gov |
| Early Phase Clinical Cancer Prevention Consortium | NIH | National Cancer Institute | 2021 to 2025 | $7,613,555 | July 7, 2020 | July 31, 2031 | SCHUETZE, SCOTT MICHAEL | reporter.nih.gov |
| Northwestern Cancer Prevention Consortium | NIH | National Cancer Institute | 2021 to 2025 | $7,062,222 | September 3, 2019 | July 31, 2031 | KHAN, SEEMA AHSAN | reporter.nih.gov |
| iCAN PREVENT: MD Anderson International Cancer Prevention Clinical Trials Consortium | NIH | National Cancer Institute | 2021 to 2025 | $7,046,172 | August 15, 2019 | July 31, 2031 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A2 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,882,445 | September 29, 2025 | September 28, 2026 | WACTAWSKI-WENDE, JEAN | reporter.nih.gov |
| WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A2 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $6,534,889 | September 29, 2025 | September 28, 2026 | STEFANICK, MARCIA | reporter.nih.gov |
| Decoding mechanisms underlying metabolic dysregulation in obesity and digestive cancer risk | NIH | National Cancer Institute | 2022 to 2025 | $6,443,697 | September 20, 2022 | August 31, 2027 | TOBIAS, DEIRDRE KAY | reporter.nih.gov |
| BASE TITLE: PREVENT PRECLINICAL DRUG DEVELOPMENT PROGRAM: PRECLINICAL EFFICACY AND INTERMEDIATE ENDPOINT BIOMAKERSTASK ORDER TITLE: VACCINES AGAINST FUSOBACTERIUM FOR FAP-AND LYNCH SYNDROME-ASSOCIA | NIH | National Cancer Institute | 2022 to 2024 | $6,227,249 | June 15, 2022 | May 15, 2025 | CLAPPER, MARGIE L. | reporter.nih.gov |
| The role of stem cells and the microenvironment in gastrointestinal cancers | NIH | National Cancer Institute | 2021 to 2025 | $5,569,272 | January 7, 2016 | August 31, 2030 | WANG, TIMOTHY CRAGIN | reporter.nih.gov |
| Innate immune sensors, inflammasomes, and inflammasome-mediated processes in cancer | NIH | National Cancer Institute | 2021 to 2025 | $5,241,422 | July 21, 2020 | June 30, 2027 | KANNEGANTI, THIRUMALA-DEVI | reporter.nih.gov |
| Comparative Modeling of Effective Policies for Colorectal Cancer Control | NIH | National Cancer Institute | 2021 to 2025 | $5,238,594 | July 1, 2025 | August 31, 2026 | ZAUBER, ANN GRAHAM | reporter.nih.gov |
| A Multimodal 3D Atlas of Colorectal Cancer Across Ages of Onset | NIH | National Cancer Institute | 2024 to 2025 | $5,159,940 | September 1, 2024 | August 31, 2029 | LAU, KEN S | reporter.nih.gov |
| Molecular Mechanism of Mammalian DNA Excision Repair and the Circadian Clock | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $5,040,955 | April 1, 2016 | August 31, 2027 | SANCAR, AZIZ | reporter.nih.gov |
| Utility of Random Biopsies in Inflammatory Bowel Disease | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $5,031,513 | July 1, 2024 | June 30, 2029 | LEWIS, JAMES D | reporter.nih.gov |
| WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A2 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $5,000,825 | September 29, 2025 | September 28, 2026 | JACKSON, REBECCA | reporter.nih.gov |
| Dose-response of aerobic training during total neoadjuvant therapy for locally advanced rectal cancer | NIH | National Cancer Institute | 2022 to 2025 | $4,937,681 | May 6, 2022 | April 30, 2027 | SCOTT, JESSICA | reporter.nih.gov |
| Precision Prevention Research Program | NIH | National Cancer Institute | 2021 to 2025 | $4,849,798 | September 1, 2020 | August 31, 2027 | CHAN, ANDREW T | reporter.nih.gov |
| Great Lakes New England Clinical Validation Center | NIH | National Cancer Institute | 2022 to 2025 | $4,820,800 | May 15, 2000 | August 31, 2027 | RICCIARDIELLO, LUIGI | reporter.nih.gov |
| Effects of Time-restricted Eating versus Daily Continuous Calorie Restriction on Body Weight and Colorectal Cancer Risk Markers among Adults with Obesity | NIH | National Cancer Institute | 2021 to 2025 | $4,635,563 | September 1, 2021 | August 31, 2027 | TUSSING-HUMPHREYS, LISA | reporter.nih.gov |
| Early to Late Events in Colorectal Neoplasia: Basic Biology to Clinical Implementation | NIH | National Cancer Institute | 2021 to 2025 | $4,608,771 | April 1, 2017 | July 31, 2031 | COFFEY, ROBERT J. | reporter.nih.gov |
| Intracellular Innate Immune Receptors in Cancer Suppression and Immunotherapy | NIH | National Cancer Institute | 2021 to 2025 | $4,541,273 | September 17, 2019 | August 31, 2026 | TING, JENNY P | reporter.nih.gov |
| Support for the Central Data Collection Center (CDCC) | NIH | National Cancer Institute | 2021 to 2025 | $4,460,745 | February 27, 2021 | February 26, 2025 | MATHEW, SUNITHA | reporter.nih.gov |
| WOMEN'S HEALTH INITIATIVE (WHI) REGIONAL CENTER (RC): TASK AREA A AND A2 | NIH | National Heart, Lung, and Blood Institute | 2021 to 2025 | $4,249,024 | September 29, 2025 | September 28, 2026 | VITOLINS, MARA | reporter.nih.gov |
| Leveraging Omics and Electronic Health Records Data to study Colorectal Adenoma genetics and Drug Repurposing | NIH | National Cancer Institute | 2025 | $4,174,595 | September 10, 2025 | August 31, 2029 | GUO, XINGYI | reporter.nih.gov |
| Time-Restricted Eating and Cancer: Clinical Outcomes, Mechanisms, and Moderators | NIH | National Cancer Institute | 2021 to 2025 | $4,123,295 | June 15, 2021 | August 31, 2026 | FIGUEIREDO, JANE C. | reporter.nih.gov |
| IL-10NanoCap® for Therapy of Familial Adenomatous Polyposis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $3,969,244 | March 7, 2019 | March 31, 2026 | AUCI, DOMINICK | reporter.nih.gov |
| Ceramides as novel drivers of metabolic dysfunction and colorectal cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,957,452 | September 2, 2022 | August 31, 2027 | PLAYDON, MARY CHRISTINE | reporter.nih.gov |
| GEMS: Genomic approach to connecting Elevated germline Mutation rates with male infertility and Somatic health | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2025 | $3,803,952 | September 1, 2021 | May 31, 2027 | HOTALING, JAMES | reporter.nih.gov |
| Columbus NCORP RFA-CA-18-016 | NIH | National Cancer Institute | 2021 to 2025 | $3,771,688 | August 1, 2014 | July 31, 2026 | RAJAGOPALAN, MALOLAN S | reporter.nih.gov |
| Optimization of a remote intervention to improve nutrition and physical activity in colorectal cancer survivors | NIH | National Cancer Institute | 2021 to 2025 | $3,771,145 | December 10, 2020 | November 30, 2025 | VAN BLARIGAN, ERIN LYNN | reporter.nih.gov |
| Rational Integration of Polygenic Risk Scores (RIPS) | NIH | National Human Genome Research Institute | 2022 to 2025 | $3,737,256 | March 10, 2022 | February 28, 2027 | PETERSON, JOSEPH F. | reporter.nih.gov |
| Blood-Based Testing for Advanced Adenoma | NIH | National Cancer Institute | 2022 to 2025 | $3,665,539 | September 12, 2022 | February 29, 2028 | SCHOEN, ROBERT E. | reporter.nih.gov |
| Effects of inflammaging on intestinal epithelial cells and aspirin chemoprevention. | NIH | National Cancer Institute | 2021 to 2025 | $3,654,173 | April 5, 2021 | March 31, 2027 | CHAN, ANDREW T | reporter.nih.gov |
| Role of the Epitranscriptome in Cancer | NIH | National Cancer Institute | 2021 to 2024 | $3,597,010 | August 1, 2019 | November 30, 2024 | GREGORY, RICHARD I. | reporter.nih.gov |
| Effectiveness and implementation of a health system intervention to improve quality of cancer care for rural, underserved patients | NIH | National Cancer Institute | 2021 to 2025 | $3,568,895 | April 1, 2021 | March 31, 2027 | CHARLTON, MARY E. | reporter.nih.gov |
| A Transdisciplinary Approach to Investigating Metabolic Dysregulation in Obese Parent and Child Dyads and Risk of Colorectal Cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,558,479 | August 16, 2022 | July 31, 2028 | HEBERT, JAMES R | reporter.nih.gov |
| Variation in tumor-associated immune profiles and colorectal cancer outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,497,316 | September 15, 2021 | August 31, 2027 | SCHMIT, STEPHANIE L. | reporter.nih.gov |
| A Phase 1-2 clinical program for the teatment of Microsatellite Stable Colorectal Cancer with the combination of SR-8541A, Botensilimab, and Balstilimab | NIH | National Cancer Institute | 2022 to 2025 | $3,457,194 | August 14, 2025 | July 31, 2028 | KAADIGE, MOHAN RAO | reporter.nih.gov |
| Chemical tools for developmental biology | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,426,216 | April 1, 2018 | June 30, 2028 | CHEN, JAMES K | reporter.nih.gov |
| Optimizing Lung Cancer Screening in Cancer Survivors | NIH | National Cancer Institute | 2021 to 2025 | $3,415,788 | July 15, 2021 | June 30, 2027 | WISNIVESKY, JUAN P | reporter.nih.gov |
| Developing and Testing a Digital Toolkit to Improve Colorectal Cancer Screening Rates in Federally Qualified Health Centers | NIH | National Cancer Institute | 2021 to 2025 | $3,348,072 | April 1, 2021 | March 31, 2027 | MILLER, SARAH J | reporter.nih.gov |
| Cancer Immune-Interception for Lynch Syndrome | NIH | National Cancer Institute | 2021 to 2025 | $3,326,163 | September 21, 2021 | August 31, 2026 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| Genetic and Molecular Dissection of Wnt Pathway Activation | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,246,880 | June 1, 2020 | July 31, 2030 | AHMED, YASMATH | reporter.nih.gov |
| Self-Management to Optimize Survivorship Care and Outcomes in Lung and Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2024 | $3,217,584 | April 2, 2020 | March 31, 2026 | SUN, VIRGINIA CHIH-YI | reporter.nih.gov |
| Active Disposable Cap for Endoscope Tip Stabilization and Complete Visualization and Dissection of Serrated Sessile Polyps | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2024 | $3,206,138 | August 7, 2018 | August 31, 2025 | MULVIHILL, MAUREEN L. | reporter.nih.gov |
| Randomized Controlled Trial of Virtual Reality for GI Cancer Pain to Improve Patient Reported Outcomes | NIH | National Cancer Institute | 2021 to 2025 | $3,190,411 | April 5, 2021 | March 31, 2027 | SPIEGEL, BRENNAN | reporter.nih.gov |
| Adipose tissue-colorectal tumor cross-talk: new targets for breaking the obesity-cancer link | NIH | National Cancer Institute | 2021 to 2025 | $3,159,289 | September 23, 2021 | August 31, 2026 | ULRICH, CORNELIA M | reporter.nih.gov |
| Mechanistic understanding of the lifecycle of a circulating hybrid cell | NIH | National Cancer Institute | 2021 to 2025 | $3,151,928 | June 1, 2021 | May 31, 2027 | WONG, MELISSA H. | reporter.nih.gov |
| Mediterranean Diet and Weight Loss: Targeting the Bile Acid/Gut Microbiome Axis to Reduce Colorectal Cancer Risk | NIH | National Cancer Institute | 2021 to 2025 | $3,149,705 | January 15, 2021 | December 31, 2026 | FITZGIBBON, MARIAN L. | reporter.nih.gov |
| Engineering Native E. coli to Detect, Report, and Treat Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2025 | $3,135,340 | September 21, 2021 | August 31, 2026 | ZARRINPAR, AMIR | reporter.nih.gov |
| Microbiota, Metabolites, and Colon Neoplasia | NIH | National Cancer Institute | 2021 to 2025 | $3,124,761 | May 1, 2021 | April 30, 2027 | ROSENBERG, DANIEL WILLIAM | reporter.nih.gov |
| Structural and functional studies of colibactin | NIH | National Cancer Institute | 2021 to 2025 | $3,124,458 | December 11, 2017 | February 29, 2028 | HERZON, SETH B. | reporter.nih.gov |
| Innate lymphoid cell regulation of the host-microbiota interactions in cancer | NIH | National Cancer Institute | 2022 to 2025 | $3,122,275 | September 20, 2022 | August 31, 2027 | SONNENBERG, GREGORY F | reporter.nih.gov |
| SPHERE (Survivorship Plan Health Record) Implementation Trial | NIH | National Cancer Institute | 2021 to 2025 | $3,117,615 | June 1, 2021 | May 31, 2027 | HAGGSTROM, DAVID ANDREW | reporter.nih.gov |
| Characterizing the Risk of Chemotherapy Side Effects Based on Epigenetic Age and Modification by Resistance Training Intervention | NIH | National Cancer Institute | 2021 to 2025 | $3,091,560 | September 8, 2021 | August 31, 2027 | BINDER, ALEXANDRA MARGARET LYNN | reporter.nih.gov |
| Epigenetic mechanisms of carcinogenesis by Parvimonas micra, an oral cavity commensal turned colon cancer pathogen | NIH | National Cancer Institute | 2021 to 2025 | $3,068,738 | September 13, 2021 | August 31, 2027 | KHAZAIE, KHASHAYARSHA | reporter.nih.gov |
| Integrative single cell analyses of inflammation-derived circulating hybrid cells to identify aggressive disease | NIH | National Cancer Institute | 2021 to 2025 | $3,044,035 | April 1, 2021 | March 31, 2027 | WONG, MELISSA H. | reporter.nih.gov |
| Therapeutic Targeting Mitochondrial C1 Metabolism | NIH | National Cancer Institute | 2021 to 2025 | $3,043,890 | January 1, 2021 | December 31, 2026 | MATHERLY, LARRY H | reporter.nih.gov |
| Mitigation of Radiation Induced Gastrointestinal Syndrome. | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,026,290 | August 1, 2023 | July 31, 2026 | NORRIS, ANDREW JOHN | reporter.nih.gov |
| CARES-REACH (Colorectal Cancer Awareness, Research, Education and Screening-Rural Expansion, Access and Capacity for Health) | NIH | National Cancer Institute | 2021 to 2024 | $3,016,341 | April 1, 2020 | March 31, 2026 | GWEDE, CLEMENT K. | reporter.nih.gov |
| Regulating cell fate and shaping the body plan during morphogenesis and their alteration during oncogenesis | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $3,000,444 | July 1, 2016 | August 31, 2026 | PEIFER, MARK A. | reporter.nih.gov |
| Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer | NIH | National Cancer Institute | 2022 to 2024 | $2,997,017 | June 3, 2022 | February 28, 2025 | BROWN, JUSTIN C | reporter.nih.gov |
| Bacterial biosensors for the prevention of gastrointestinal cancers | NIH | National Cancer Institute | 2021 to 2025 | $2,993,830 | May 18, 2020 | April 30, 2029 | HASTY, JEFF M | reporter.nih.gov |
| The role of RAMS11 in colorectal cancer progression and treatment resistance | NIH | National Cancer Institute | 2021 to 2025 | $2,937,715 | August 10, 2021 | July 31, 2026 | MAHER, CHRISTOPHER A | reporter.nih.gov |
| Behavioral Economic Approaches for Population-based Colorectal Cancer Screening | NIH | National Cancer Institute | 2022 to 2025 | $2,932,568 | December 17, 2021 | November 30, 2026 | MEHTA, SHIVAN JATIN | reporter.nih.gov |
| The EPICS (Engaging Primary care in Cancer Survivorship) study: A trial of novel models of care for cancer survivors | NIH | National Cancer Institute | 2021 to 2024 | $2,922,559 | June 1, 2020 | September 30, 2025 | HAHN, ERIN ELIZABETH | reporter.nih.gov |
| Innate Immune Mechanisms Contributing to Cancer Growth in Obesity | NIH | National Cancer Institute | 2021 to 2025 | $2,914,829 | July 1, 2021 | June 30, 2026 | ENGLEMAN, EDGAR G. | reporter.nih.gov |
| Non-invasive imaging of the anti-tumor immune response | NIH | National Cancer Institute | 2021 to 2025 | $2,904,564 | December 14, 2020 | November 30, 2026 | PISHESHA, NOVALIA | reporter.nih.gov |
| Tumor selective inhibition of the WNT pathway | NIH | National Cancer Institute | 2022 to 2025 | $2,875,859 | September 22, 2022 | August 31, 2027 | DOW, LUKAS EDWARD | reporter.nih.gov |
| Understanding and Harnessing Microbial Reprogramming to Combat Carcinogenic Colibactin in Colorectal Cancer | NIH | National Cancer Institute | 2025 | $2,864,671 | September 10, 2025 | August 31, 2029 | LI, JIAHE | reporter.nih.gov |
| Interdisciplinary Epidemiologic Consortium to Investigate T-cell Response in Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,822,799 | May 1, 2020 | October 31, 2026 | PETERS, ULRIKE | reporter.nih.gov |
| Overcoming adaptive feedback resistance to KRAS inhibition in colorectal cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,815,123 | April 1, 2022 | March 31, 2027 | CORCORAN, RYAN BRUCE | reporter.nih.gov |
| Rural Community Support for Colonoscopy | NIH | National Cancer Institute | 2021 to 2025 | $2,814,878 | March 8, 2021 | February 28, 2027 | COLE, ALLISON | reporter.nih.gov |
| New Epidemiologic Methods for Reducing Measurement Error and Misclassification Bias in Cancer Epidemiology | NIH | National Cancer Institute | 2023 to 2025 | $2,790,776 | September 21, 2023 | August 31, 2027 | WANG, MOLIN | reporter.nih.gov |
| DNA Adduct Detection and Repair in Mammalian Cells | NIH | National Institute of Environmental Health Sciences | 2021 to 2025 | $2,783,115 | September 17, 2021 | June 30, 2027 | SANCAR, AZIZ | reporter.nih.gov |
| Treating colon cancer by regulating intestinal immunity through microbial metabolism | NIH | National Cancer Institute | 2021 to 2025 | $2,772,249 | June 1, 2021 | May 31, 2027 | ARPAIA, NICHOLAS | reporter.nih.gov |
| Multi-cancer early detection using cell-free DNA methylome analysis | NIH | National Cancer Institute | 2023 to 2025 | $2,757,500 | September 19, 2023 | August 31, 2028 | ZHOU, XIANGHONG JASMINE | reporter.nih.gov |
| Community Partnership for Telehealth Solutions to Counter Misinformation and Achieve Equity (PRIME) | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2024 | $2,752,440 | September 18, 2022 | May 2, 2024 | PETRIK, AMANDA F. | reporter.nih.gov |
| Integration of epidemiology, pathology, immunology and outcomes in colorectal cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,735,518 | September 22, 2022 | August 31, 2027 | GRUBER, STEPHEN B | reporter.nih.gov |
| AND-gated Synthetic Biomarkers for Early Detection of Liver Metastasis | NIH | National Cancer Institute | 2021 to 2025 | $2,734,586 | September 23, 2021 | August 31, 2027 | KWONG, GABRIEL A | reporter.nih.gov |
| Obesity, sedentary behaviors, and diet quality for prevention and early detection of early-onset colorectal neoplasia | NIH | National Cancer Institute | 2021 to 2025 | $2,729,669 | July 1, 2020 | June 30, 2027 | CAO, YIN | reporter.nih.gov |
| The ASPIRES Study: Activating Cancer Survivors and their Primary Care Providers to Increase Colorectal Cancer Screening | NIH | National Cancer Institute | 2021 to 2025 | $2,725,531 | March 1, 2021 | March 31, 2025 | HENDERSON, TARA OLIVE | reporter.nih.gov |
| Cancer Immune-Interception in a Spontaneous Non-Human Primate Model of Lynch Syndrome | NIH | National Cancer Institute | 2022 to 2025 | $2,721,586 | August 22, 2022 | July 31, 2027 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| Association between pre-diagnosis hepatic fat infiltration and risk of liver metastasis and mortality in a large cohort of stage I-III colorectal cancer survivors | NIH | National Cancer Institute | 2022 to 2025 | $2,716,606 | September 23, 2022 | August 31, 2027 | GIOVANNUCCI, EDWARD | reporter.nih.gov |
| Understanding the Contribution of Colorectal Cancer Tumor Characteristics to Disparities in Colorectal Cancer Survival | NIH | National Cancer Institute | 2021 to 2025 | $2,714,017 | July 15, 2021 | June 30, 2027 | WARREN ANDERSEN, SHANEDA | reporter.nih.gov |
| Time-dependent and bidirectional effect of oxidative stress - a missing piece of the free radical theory of cancer and its potential implications | NIH | National Cancer Institute | 2021 to 2025 | $2,701,769 | December 1, 2019 | November 30, 2026 | YANG, GONG | reporter.nih.gov |
| Multiscale Modeling to Optimize Inhibition of Oncogenic ERK Pathway Signaling | NIH | National Cancer Institute | 2021 to 2024 | $2,681,014 | February 7, 2020 | January 31, 2025 | LEMMON, MARK A | reporter.nih.gov |
| Spermidine as a New Therapy for Colitis and Chemopreventive for Colitis-associated Carcinogenesis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,674,708 | March 31, 2021 | February 28, 2026 | WILSON, KEITH T. | reporter.nih.gov |
| Preclinical Development of First-in-Class GSTO1 Degraders for Colorectal Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,673,041 | August 2, 2022 | July 31, 2027 | NEAMATI, NOURI | reporter.nih.gov |
| Fiber-rich Foods to Treat Obesity and Prevent Colon Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,669,304 | July 15, 2020 | June 30, 2026 | HARTMAN, TERRYL J. | reporter.nih.gov |
| Novel Biomarkers for Cancer-Related Fatigue: Integrating Metabolomics, Genomics and Behaviors | NIH | National Institute of Nursing Research | 2021 to 2024 | $2,663,131 | May 28, 2020 | March 31, 2025 | FIGUEIREDO, JANE C. | reporter.nih.gov |
| Advancing equity in colorectal cancer genetic risk prediction through expansion of racial/ethnic minority representation | NIH | National Cancer Institute | 2021 to 2024 | $2,661,057 | July 1, 2020 | June 30, 2025 | PETERS, ULRIKE | reporter.nih.gov |
| An integrative omics approach to investigate gene-environment interaction in colorectal cancer risk | NIH | National Cancer Institute | 2023 to 2025 | $2,659,982 | June 1, 2023 | May 31, 2028 | PETERS, ULRIKE | reporter.nih.gov |
| Discovery and verification of methylated circulating tumor DNA markers for the detection of colorectal cancer in subjects under 50 years of age | NIH | National Cancer Institute | 2021 to 2024 | $2,647,966 | July 1, 2021 | June 30, 2026 | HITCHINS, MEGAN P | reporter.nih.gov |
| Expansion of Tumoroid Models for Precise Treatment of the Rectal Cancer Patient | NIH | National Cancer Institute | 2021 to 2025 | $2,633,017 | March 1, 2025 | June 30, 2025 | SMITH, JESSE JOSHUA | reporter.nih.gov |
| Coffee and metabolites modulating the gut microbiome for improved colorectal cancer survival | NIH | National Cancer Institute | 2022 to 2025 | $2,628,801 | June 2, 2022 | May 31, 2027 | SONG, MINGYANG | reporter.nih.gov |
| IMProving Adherence to Colonoscopy through Teams and Technology (IMPACTT) | NIH | National Cancer Institute | 2022 to 2025 | $2,621,250 | May 16, 2022 | February 28, 2027 | SARKAR, URMIMALA | reporter.nih.gov |
| Intestinal surveillance by intraepithelial lymphocytes | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2025 | $2,589,419 | July 1, 2017 | April 30, 2026 | MUCIDA, DANIEL S | reporter.nih.gov |
| Investigation of FadA adhesin from Fusobacterium nucleatum | NIH | National Institute of Dental & Craniofacial Research | 2021 to 2024 | $2,580,121 | September 10, 2020 | August 31, 2026 | HAN, YIPING | reporter.nih.gov |
| Personalized Provider Selection to Reduce Surgical Disparities | NIH | National Institute on Minority Health and Health Disparities | 2022 to 2025 | $2,578,451 | May 19, 2022 | February 28, 2027 | KELZ, RACHEL | reporter.nih.gov |
| ALOX15 regulation of colon cancer invasiveness via PI3P-linoleic acid metabolism | NIH | National Cancer Institute | 2022 to 2025 | $2,576,142 | January 1, 2022 | April 30, 2027 | SHUREIQI, IMAD | reporter.nih.gov |
| Kinome-guided Targeting of Cooperative Dependencies in BRAF Mutated Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,574,186 | June 1, 2019 | May 31, 2029 | COPPE, JEAN-PHILIPPE FRANCOIS MARIE | reporter.nih.gov |
| Unique targeting of PPARβ/δ regulation for cancer prevention and therapy | NIH | National Cancer Institute | 2021 to 2024 | $2,559,468 | December 6, 2019 | November 30, 2025 | PETERS, JEFFREY M | reporter.nih.gov |
| Inhibition of the Wnt Receptor Complex by the Tumor Suppressor Adenomatous Polyposis Coli | NIH | National Cancer Institute | 2021 to 2024 | $2,543,570 | July 15, 2020 | June 30, 2026 | AHMED, YASMATH | reporter.nih.gov |
| Circadian Clock and Myc-dependent Regulation of Cellular Transformation | NIH | National Cancer Institute | 2022 to 2025 | $2,542,136 | January 1, 2022 | December 31, 2026 | MASRI, SELMA | reporter.nih.gov |
| A Statistical Physics Framework for Understanding the Role of Repeat RNA in Tumor Immunity | NIH | National Cancer Institute | 2021 to 2024 | $2,539,571 | September 15, 2020 | August 31, 2025 | GREENBAUM, BENJAMIN | reporter.nih.gov |
| SUMO Modification and Cancer Therapy | NIH | National Cancer Institute | 2021 to 2025 | $2,526,679 | May 1, 2021 | April 30, 2026 | CHEN, YUAN | reporter.nih.gov |
| Design and characterization of bacterial population dynamics in solid tumor models | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $2,515,679 | August 1, 2021 | April 30, 2025 | HASTY, JEFF M | reporter.nih.gov |
| Role of Erbb3 kinase activity in colorectal tumorigenesis. | NIH | National Cancer Institute | 2021 to 2025 | $2,509,394 | February 9, 2021 | January 31, 2026 | WANG, ZHENGHE | reporter.nih.gov |
| Fluorescence guided nerve sparing during colorectal cancer surgery using local application of a near infrared nerve fluorophore | NIH | National Cancer Institute | 2025 | $2,491,138 | August 15, 2025 | July 31, 2029 | GIBBS, SUMMER LYNNE | reporter.nih.gov |
| Leveraging Novel Randomized Clinical Trials of Vitamin D Supplementation in Patients with Colorectal Cancer: Impact on Survival and Anti-Tumor Immunity | NIH | National Cancer Institute | 2021 to 2025 | $2,477,583 | March 15, 2017 | June 30, 2027 | NG, KIMMIE | reporter.nih.gov |
| Mouse models of Kras-mutant colorectal cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,463,211 | July 1, 2020 | June 30, 2026 | HAIGIS, KEVIN | reporter.nih.gov |
| Tumor Organoid-Mediated Drug Testing and Clonality Analysis in Peritoneal Surface Disease of Intestinal Origin | NIH | National Cancer Institute | 2021 to 2025 | $2,463,080 | March 1, 2021 | February 28, 2027 | VOTANOPOULOS, KONSTANTINOS | reporter.nih.gov |
| Deconstructing and targeting aneuploidy in human cancer - Resubmission - 1 | NIH | National Cancer Institute | 2021 to 2025 | $2,458,661 | April 1, 2021 | March 31, 2026 | DAVOLI, TERESA | reporter.nih.gov |
| Developing novel bispecific antibodies for cancer treatment | NIH | National Cancer Institute | 2021 to 2025 | $2,437,200 | July 1, 2021 | June 30, 2027 | FAN, ZHEN | reporter.nih.gov |
| Polymerase epsilon-based mouse and derived organoid models of intestinal cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,435,094 | September 15, 2022 | August 31, 2027 | CASTRILLON, DIEGO H | reporter.nih.gov |
| Role of immune regulation in colorectal cancer chemotherapeutic response | NIH | National Cancer Institute | 2021 to 2025 | $2,422,671 | September 1, 2021 | August 31, 2026 | LU, JUN | reporter.nih.gov |
| Advancing Access in Cancer Care: Investigating Health-Related Social Needs and Colonoscopy Follow-Up Among FQHC Patients | NIH | National Cancer Institute | 2023 to 2025 | $2,422,382 | May 4, 2023 | April 30, 2028 | DOUBENI, CHYKE ABADAMA | reporter.nih.gov |
| Upgrading rigor and efficiency of germline cancer gene variant classification for the 2020s | NIH | National Cancer Institute | 2022 to 2025 | $2,422,203 | March 1, 2022 | January 31, 2027 | TAVTIGIAN, SEAN VAHRAM | reporter.nih.gov |
| Designing a Plan of Action for Better Access and Quality of Surgery for African-Americans with Gastrointestinal Cancers in the Deep South | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2024 | $2,406,877 | June 15, 2020 | January 31, 2026 | PISU, MARIA | reporter.nih.gov |
| SIRPant Technology for anti-Cancer Immunity | NIH | National Cancer Institute | 2021 to 2024 | $2,399,999 | September 22, 2021 | July 31, 2025 | MCCURLEY, NATHANAEL | reporter.nih.gov |
| The Gut Microbiome, Lifestyle, and Colorectal Neoplasia | NIH | National Cancer Institute | 2022 to 2025 | $2,397,399 | May 1, 2022 | April 30, 2027 | SONG, MINGYANG | reporter.nih.gov |
| Optical imaging to predict cell-level genetic heterogeneity and treatment sensitivity in colorectal cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,396,849 | June 8, 2018 | May 31, 2025 | DEMING, DUSTIN A | reporter.nih.gov |
| Time-varying relationships between built environment factors, colon and rectum cancer prognosis, and survival | NIH | National Cancer Institute | 2022 to 2025 | $2,370,003 | May 1, 2022 | April 30, 2027 | PLASCAK, JESSE JOHN | reporter.nih.gov |
| NOT-CA-24-111 Improving Strategies for Cancer Reduction through Early-detection and ENgagement (I-SCREEN) | NIH | National Cancer Institute | 2024 to 2025 | $2,357,813 | February 14, 2024 | December 31, 2027 | COOK, LINDA S | reporter.nih.gov |
| Engineering immunotherapeutic probiotics to mitigate irAE | NIH | National Cancer Institute | 2021 to 2024 | $2,351,179 | January 21, 2020 | December 31, 2024 | DANINO, TAL | reporter.nih.gov |
| A cloud-based digital health navigation program for colorectal cancer screening | NIH | National Cancer Institute | 2023 to 2025 | $2,350,065 | April 1, 2023 | June 30, 2027 | MILLER, DAVID P | reporter.nih.gov |
| Functional optical imaging for rapid, label-free predictions of treatment response and clonal evolution in patient-derived cancer organoids | NIH | National Cancer Institute | 2023 to 2025 | $2,348,049 | April 1, 2023 | March 31, 2028 | SKALA, MELISSA CAROLINE | reporter.nih.gov |
| MyGI Diet for Colorectal Cancer Prevention | NIH | National Cancer Institute | 2021 to 2025 | $2,345,455 | July 1, 2021 | June 30, 2027 | BUIS, LORRAINE R | reporter.nih.gov |
| Advancing Precision Oncology in a Humanized, Fully Autologous Mouse Model | NIH | National Cancer Institute | 2021 to 2024 | $2,342,069 | March 1, 2020 | February 28, 2026 | FIELDS, RYAN C | reporter.nih.gov |
| Real time colon histopathology by infrared spectroscopic imaging | NIH | National Cancer Institute | 2021 to 2025 | $2,305,182 | July 1, 2021 | June 30, 2027 | BHARGAVA, ROHIT | reporter.nih.gov |
| How Patterned Mesenchymal-Epithelial interactions Shape Intestinal Crypts | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,304,272 | February 15, 2022 | January 31, 2026 | KLEIN, OPHIR D | reporter.nih.gov |
| Optimizing colorectal cancer prevention: a multi-disciplinary, population-based investigation of serrated polyps using risk prediction and modeling | NIH | National Cancer Institute | 2021 to 2024 | $2,300,681 | July 1, 2020 | June 30, 2025 | BUTTERLY, LYNN F | reporter.nih.gov |
| Metabolism of cancer chemotherapeutics by the human gut microbiome | NIH | National Cancer Institute | 2023 to 2025 | $2,300,078 | September 1, 2023 | August 31, 2028 | TURNBAUGH, PETER JAMES | reporter.nih.gov |
| Community Partnership for Telehealth Solutions to Convey Information and Enhance Care (PRIME) | NIH | National Institute on Minority Health and Health Disparities | 2024 to 2025 | $2,298,376 | September 18, 2022 | April 30, 2027 | CORONADO, GLORIA D. | reporter.nih.gov |
| Sirtuins and Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,289,538 | June 15, 2022 | May 31, 2027 | HAIGIS, MARCIA | reporter.nih.gov |
| HFH-MSU CSRN ACCrual Enrollment and Screening Site | NIH | National Cancer Institute | 2024 to 2025 | $2,289,116 | March 7, 2025 | December 31, 2027 | NESLUND-DUDAS, CHRISTINE MARIE | reporter.nih.gov |
| Coordination of Innate and Adaptive Immunity in Intestinal Barrier Defense | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,271,848 | March 1, 2022 | February 28, 2027 | WEAVER, CASEY T | reporter.nih.gov |
| Pathogenesis of Early Onset Colorectal Cancer: Microbiome Contributions and Mechanisms | NIH | National Cancer Institute | 2021 to 2025 | $2,266,043 | September 23, 2021 | August 31, 2026 | SEARS, CYNTHIA | reporter.nih.gov |
| A cancer-derived truncating mutation in disease penetrance and progression of MSI CRC | NIH | National Cancer Institute | 2021 to 2024 | $2,262,153 | August 6, 2020 | November 30, 2025 | LIANG, CHENGYU | reporter.nih.gov |
| The selective advantage of mismatch repair loss in colonic stem cells | NIH | National Cancer Institute | 2021 to 2025 | $2,253,508 | April 1, 2021 | March 31, 2027 | HEINEN, CHRISTOPHER D. | reporter.nih.gov |
| Molecular mechanisms driving mesenchymal colorectal cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,244,982 | March 17, 2021 | February 28, 2026 | MOSCAT, JORGE | reporter.nih.gov |
| Role of Receptor Tyrosine Kinase cross-talk in colorectal cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,240,946 | May 12, 2021 | April 30, 2027 | SINGH, BHUMINDER | reporter.nih.gov |
| PROSPECT-Global Consortium and Risk Factor Discovery | NIH | National Cancer Institute | 2024 to 2025 | $2,222,328 | May 1, 2024 | April 30, 2026 | CAO, YIN | reporter.nih.gov |
| Colorectal carcinogenesis and Fusobacterium nucleatum: oncomicrobe, oncometabolites, and oncoimmunology | NIH | National Cancer Institute | 2021 to 2025 | $2,221,814 | March 18, 2011 | July 31, 2027 | GARRETT, WENDY S. | reporter.nih.gov |
| Ethnicity and Nativity in Cancer - Latino & Asian Enclaves: The ENCLAVE Study | NIH | National Cancer Institute | 2021 to 2024 | $2,219,992 | April 1, 2020 | March 31, 2026 | SHARIFF-MARCO, SALMA | reporter.nih.gov |
| Ubiquitination, Intestinal Homeostasis and Cancer | NIH | National Cancer Institute | 2022 to 2025 | $2,211,716 | September 1, 2022 | August 31, 2027 | MA, AVERIL I | reporter.nih.gov |
| Strengthening gut barrier integrity with beneficial microbes to increase lifespan and healthspan | NIH | National Institute on Aging | 2022 to 2025 | $2,197,864 | September 15, 2021 | May 31, 2027 | CROTT, JIMMY W | reporter.nih.gov |
| The role of the senescent microenvironment on cancer initiating cells in the colon. | NIH | National Institute on Aging | 2021 to 2025 | $2,183,637 | September 30, 2021 | August 31, 2026 | GRADY, WILLIAM MALLORY | reporter.nih.gov |
| Mechanisms of Dynamic Transcriptional Reprogramming in Metastasis Stem Cells | NIH | National Cancer Institute | 2022 to 2025 | $2,177,395 | March 1, 2022 | January 31, 2027 | GANESH, KARUNA | reporter.nih.gov |
| Role of PTPRT in colon cancer progression and metastasis | NIH | National Cancer Institute | 2022 to 2025 | $2,174,026 | August 24, 2022 | July 31, 2027 | WANG, ZHENGHE | reporter.nih.gov |
| Uncovering colorectal cancer etiology and biology by integrating proteomics with other omics data | NIH | National Cancer Institute | 2023 to 2025 | $2,171,240 | April 11, 2023 | March 31, 2028 | GUO, XINGYI | reporter.nih.gov |
| Inactivation of MSH3 in Colorectal Cancer and Race | NIH | National Cancer Institute | 2022 to 2025 | $2,166,564 | August 1, 2021 | July 31, 2026 | CARETHERS, JOHN M | reporter.nih.gov |
| Population-based assessment of patient-reported outcomes in adults living with metastatic colorectal cancer | NIH | National Cancer Institute | 2023 to 2025 | $2,151,172 | September 19, 2023 | August 31, 2028 | POTOSKY, ARNOLD L | reporter.nih.gov |
| Characterization and modeling of m6A RNA methylation in cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,150,624 | September 1, 2020 | May 31, 2026 | LIANG, HAN | reporter.nih.gov |
| Aggressive colorectal cancer subtypes and social disadvantage in a racially diverse cohort | NIH | National Cancer Institute | 2022 to 2025 | $2,146,832 | June 1, 2021 | December 31, 2026 | ROZEK, LAURA | reporter.nih.gov |
| Targeting plasma membrane spatial dynamics to suppress aberrant Wnt signaling | NIH | National Cancer Institute | 2021 to 2024 | $2,143,591 | September 3, 2020 | May 31, 2026 | CHAPKIN, ROBERT STEPHEN | reporter.nih.gov |
| Discovery of small molecule inhibitors for protein N-terminal acetyltransferase D | NIH | National Cancer Institute | 2022 to 2025 | $2,138,837 | December 1, 2021 | November 30, 2026 | HUANG, RONG | reporter.nih.gov |
| Mechanistic dissection and inhibitor targeting of autophagy in RAS driven cancers | NIH | National Cancer Institute | 2021 to 2025 | $2,137,708 | July 1, 2025 | June 30, 2027 | BRYANT, KIRSTEN L | reporter.nih.gov |
| Targeting colorectal cancer stem cells with ALDH1B1 antagonists | NIH | National Cancer Institute | 2021 to 2025 | $2,133,438 | June 1, 2021 | May 31, 2026 | CHEN, JAMES K | reporter.nih.gov |
| Gut microbiota-related mechanisms that impact colorectal cancer risk after bariatric surgery | NIH | National Cancer Institute | 2023 to 2025 | $2,129,873 | September 7, 2023 | August 31, 2028 | YU, DANXIA | reporter.nih.gov |
| Biomaterials for modulating the gut microbiome for immune activation | NIH | National Cancer Institute | 2022 to 2025 | $2,127,257 | May 1, 2022 | April 30, 2027 | MOON, JAMES J. | reporter.nih.gov |
| Development of multifunctional drug and immune modulator delivery nanoparticles for the treatment of cancer patients with comorbid atherosclerosis | NIH | National Cancer Institute | 2021 to 2025 | $2,122,501 | February 1, 2021 | January 31, 2026 | YANG, LILY | reporter.nih.gov |
| Health and Financial Costs of Unequal Care: Colorectal Cancer as a Case Study | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $2,119,031 | September 23, 2023 | March 31, 2028 | RUTTER, CAROLYN M | reporter.nih.gov |
| Exercise as Interception Therapy in Primary High Risk Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,107,239 | September 3, 2020 | June 30, 2026 | JONES, LEE W | reporter.nih.gov |
| TLR5 enhancement of liver-directed radiotherapy plus immune checkpoint blockade against irradiated liver metastasis and abscopal tumors | NIH | National Cancer Institute | 2023 to 2025 | $2,103,321 | June 9, 2023 | May 31, 2028 | BRACKETT, CRAIG M. | reporter.nih.gov |
| Molecular and functional investigation of the role of CD1 in gamma delta T cell surveillance | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,098,612 | September 22, 2020 | August 31, 2025 | ADAMS, ERIN JUNE | reporter.nih.gov |
| Folic Acid Supplementation and Colitis-associated Colon Carcinogenesis | NIH | National Cancer Institute | 2022 to 2025 | $2,082,906 | May 11, 2022 | April 30, 2027 | CLAPPER, MARGIE L. | reporter.nih.gov |
| Understanding intrinsic resistance to direct KRAS inhibition in colorectal cancers | NIH | National Cancer Institute | 2022 to 2025 | $2,067,058 | January 1, 2022 | December 31, 2026 | GORDAN, JOHN D | reporter.nih.gov |
| Deep molecular and cellular profiling of colorectal cancer tumor and immune microenvironment in Alaska Native people | NIH | National Cancer Institute | 2023 to 2025 | $2,066,819 | May 25, 2023 | April 30, 2028 | HUYGHE, JEROEN R | reporter.nih.gov |
| Biomarkers, mechanisms and modulation of oxidative stress associated risk factors in carcinogenesis | NIH | Office of the Director, National Institutes of Health | 2022 to 2025 | $2,065,432 | September 14, 2022 | December 31, 2025 | LI, YUN ROSE | reporter.nih.gov |
| Regulation of Zbtb44-Eomes complex in CD8+T cells and anti-tumor immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,053,464 | March 24, 2021 | February 28, 2027 | POOJARY, VENUPRASAD K | reporter.nih.gov |
| Investigating a master regulator of large intestine stem cells | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $2,038,576 | August 1, 2021 | July 31, 2025 | RAFII, SHAHIN | reporter.nih.gov |
| Circadian Clock Disruption and Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2025 | $2,037,646 | March 1, 2020 | July 31, 2030 | MASRI, SELMA | reporter.nih.gov |
| Mitochondria-to-Nucleus Signaling in Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,035,169 | December 1, 2019 | November 30, 2024 | SHADEL, GERALD | reporter.nih.gov |
| Impact of CLDN1 inhibition on chemoresistance and metastasis of colon cancer | NIH | National Cancer Institute | 2021 to 2024 | $2,033,632 | February 12, 2021 | January 31, 2026 | DHAWAN, PUNITA | reporter.nih.gov |
| Personalizing Post-Polypectomy Surveillance for Colorectal Cancer Prevention | NIH | National Cancer Institute | 2023 to 2025 | $2,027,204 | September 19, 2023 | August 31, 2028 | LEE, JEFFREY KUANG ZOU | reporter.nih.gov |
| UNCOVER: underlying novel causes of onset of very early cancer research | NIH | National Cancer Institute | 2021 to 2025 | $2,020,293 | September 6, 2021 | August 31, 2027 | YANG, WAN | reporter.nih.gov |
| Addressing the Biology of Health Disparities by Targeting Geographical Ancestry-driven Variants of Immunity | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $2,010,639 | September 20, 2021 | May 31, 2027 | KIMBRO, KEVIN SEAN | reporter.nih.gov |
| Analyzing the Hypersensitivity of MMR-deficient Colorectal Cancers to mTOR Inhibition and the Response of Cancer Stem Cells | NIH | National Cancer Institute | 2021 to 2025 | $2,004,798 | April 1, 2021 | March 31, 2026 | EDELMANN, WINFRIED | reporter.nih.gov |
| Small Molecule MYC Degraders as Novel Cancer Therapeutic Agents | NIH | National Cancer Institute | 2023 to 2024 | $2,000,000 | April 5, 2022 | August 31, 2025 | FEI, DENNIS LIANG | reporter.nih.gov |
| Immunotherapy to deplete key Treg subsets in solid tumors | NIH | National Cancer Institute | 2024 to 2025 | $2,000,000 | August 13, 2024 | July 31, 2027 | SUZDAK, PETER DAVID | reporter.nih.gov |
| Antigen-targeted activation of Topo1 inhibitors via click chemistry | NIH | National Cancer Institute | 2024 to 2025 | $1,999,929 | September 6, 2024 | August 31, 2026 | MEJIA ONETO, JOSE M | reporter.nih.gov |
| Risk stratified survivorship care pathways for early-onset colorectal cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,993,826 | March 21, 2023 | February 29, 2028 | WALLNER, LAUREN P | reporter.nih.gov |
| Engineered Colon Cancer Tissue to Examine the Role of the Obese Microenvironment in Tumor Aggressiveness | NIH | National Cancer Institute | 2022 to 2025 | $1,993,201 | July 1, 2022 | June 30, 2027 | LIPKE, ELIZABETH A | reporter.nih.gov |
| Topic Number 431Cancer Treatment Technologies for Low-Resource Settings | NIH | National Cancer Institute | 2024 | $1,987,032 | September 12, 2024 | September 11, 2026 | MONTY, NATHAN | reporter.nih.gov |
| Optimal Colorectal Cancer Surveillance Strategy for Lynch Syndrome by Genotype | NIH | National Cancer Institute | 2021 to 2025 | $1,983,781 | August 1, 2021 | July 31, 2026 | HUR, CHIN | reporter.nih.gov |
| Improved Treatment of Colorectal Cancer with CF10 | NIH | National Cancer Institute | 2023 to 2024 | $1,983,010 | May 1, 2023 | April 30, 2026 | GMEINER, WILLIAM H. | reporter.nih.gov |
| Novel Targeted Anticancer Agents from Marine Cyanobacteria | NIH | National Cancer Institute | 2021 to 2025 | $1,978,529 | March 6, 2013 | January 31, 2030 | LUESCH, HENDRIK | reporter.nih.gov |
| Targeting immunoproteasome-mediated antigen presentation in colorectal cancer immunotherapy | NIH | National Cancer Institute | 2022 to 2025 | $1,972,182 | January 1, 2022 | December 31, 2026 | ZHANG, XINNA | reporter.nih.gov |
| Gasdermin E and pyroptosis in cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,970,899 | April 3, 2020 | March 31, 2025 | LIEBERMAN, JUDY | reporter.nih.gov |
| Mechanisms of PIK3CA helical domain mutations driving colorectal tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $1,968,370 | August 6, 2021 | July 31, 2026 | WANG, ZHENGHE | reporter.nih.gov |
| A Cereblon signaling network in Wnt-driven cancers | NIH | National Cancer Institute | 2023 to 2025 | $1,966,061 | March 10, 2023 | February 29, 2028 | AHMED, YASMATH | reporter.nih.gov |
| Wnt Pathway Regulation of Gastric Stem Cell Function | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,965,318 | February 1, 2022 | January 31, 2026 | SAMUELSON, LINDA C. | reporter.nih.gov |
| Multiplexed drug testing of micro-dissected tumors using a microfluidic platform with integrated electrochemical aptasensors | NIH | National Cancer Institute | 2023 to 2025 | $1,961,711 | April 1, 2023 | March 31, 2028 | FOLCH, ALBERT | reporter.nih.gov |
| Diagnosis of Cancer in the Emergency Room - Explaining Persistent Disparities | NIH | National Cancer Institute | 2021 to 2025 | $1,957,730 | July 1, 2021 | June 30, 2027 | THOMPSON, CAROLINE AVERY | reporter.nih.gov |
| Rapid Adoption of Robotic Surgery: Risks, Benefits, and Unintended Consequences | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,956,732 | January 21, 2022 | December 31, 2025 | DIMICK, JUSTIN BRIGHAM | reporter.nih.gov |
| How beta-catenin expands Foxp3+RORgammat+ Pro-inflammatoryT-regulatory cells - Renewal | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $1,948,254 | July 1, 2022 | June 30, 2025 | GOUNARI, FOTINI | reporter.nih.gov |
| REmote symptom COllection to improVE postopeRative care (RECOVER) | NIH | National Institute on Minority Health and Health Disparities | 2023 to 2025 | $1,946,544 | July 15, 2023 | December 31, 2027 | SHARA, NAWAR | reporter.nih.gov |
| Quantitative top-down proteomics of human colorectal cancer cells and tumors | NIH | National Cancer Institute | 2021 to 2025 | $1,944,242 | February 10, 2021 | January 31, 2027 | SUN, LIANGLIANG | reporter.nih.gov |
| Early response to radiotherapy and immunotherapy in rectal cancer: an integrated molecular, cellular, and spatial approach | NIH | National Cancer Institute | 2023 to 2025 | $1,938,556 | August 1, 2023 | July 31, 2028 | AGUILERA, TODD A | reporter.nih.gov |
| Registering Cancer Recurrences in the Georgia Cancer Registry | NIH | National Cancer Institute | 2021 to 2024 | $1,933,624 | February 15, 2019 | July 31, 2025 | WARD, KEVIN C | reporter.nih.gov |
| Implementing evidence based colorectal cancer screening in rural clinics | NIH | National Cancer Institute | 2023 to 2025 | $1,922,166 | January 1, 2023 | December 31, 2027 | CHAMPION, VICTORIA LEE | reporter.nih.gov |
| Therapeutic targeting of Wnt signaling in cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,913,719 | December 1, 2022 | November 30, 2027 | CHEN, CHUO | reporter.nih.gov |
| Novel Post-surgical Incision Management Device to Prevent Ostomy Complications | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,909,235 | March 1, 2023 | February 28, 2027 | OBST, ANDREW T | reporter.nih.gov |
| Defining the function of Complex I truncating mutations in cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,896,011 | January 1, 2023 | December 31, 2027 | REZNIK, EDUARD | reporter.nih.gov |
| Multilevel health system intervention to increase surveillance colonoscopy for high-risk colorectal polyps | NIH | National Cancer Institute | 2022 to 2025 | $1,892,563 | August 1, 2022 | November 30, 2027 | MAY, FOLASADE POPOOLA | reporter.nih.gov |
| Assessing the long-term impacts of the COVID-19 pandemic on disparities in cancer screening and follow-up | NIH | National Cancer Institute | 2021 to 2024 | $1,886,468 | July 15, 2021 | July 2, 2024 | DICKERSON, JOHN F | reporter.nih.gov |
| Understanding the role and clinical potential of dominant immune suppressive myeloid-cell responses in human cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,881,297 | September 10, 2021 | August 31, 2026 | SCHALPER, KURT A | reporter.nih.gov |
| Mismatch Repair and Carcinogenesis | NIH | National Cancer Institute | 2021 to 2025 | $1,880,282 | April 1, 1995 | June 30, 2027 | FISHEL, RICHARD | reporter.nih.gov |
| Understanding the mechanisms of iron addiction in colon cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,878,533 | July 1, 2020 | June 30, 2025 | SHAH, YATRIK M | reporter.nih.gov |
| The kynurenine-AHR pathway in biomass production | NIH | National Cancer Institute | 2021 to 2024 | $1,873,349 | March 1, 2020 | February 28, 2026 | CONACCI-SORRELL, MARALICE | reporter.nih.gov |
| Defining the role of tumoral MHC Class I Expression in Mediating Colorectal Cancer Racial Disparities | NIH | National Cancer Institute | 2023 to 2025 | $1,868,361 | August 1, 2023 | July 31, 2028 | RUBINSTEIN, MARK P | reporter.nih.gov |
| Advancing MRI technology for early diagnosis of liver metastases | NIH | National Cancer Institute | 2021 to 2024 | $1,861,579 | December 1, 2019 | November 30, 2025 | ALTBACH, MARIA I. | reporter.nih.gov |
| Long-Term Adverse Outcomes Among Rural Cancer Survivors in a Population-Based Cohort | NIH | National Cancer Institute | 2021 to 2024 | $1,858,613 | July 16, 2020 | June 30, 2025 | CAMP, NICOLA J. | reporter.nih.gov |
| Elucidating the role of gut microbiota in colitis-associated colorectal cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,850,100 | January 1, 2023 | December 31, 2027 | CHEN, RU | reporter.nih.gov |
| Multi-modal machine learning to guide adjuvant therapy in surgically resectable colorectal cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,848,386 | May 2, 2023 | April 30, 2028 | SHEN, JEANNE | reporter.nih.gov |
| Control of regulatory T cells by IL-17 in colorectal cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,841,987 | June 1, 2021 | May 31, 2026 | WANG, KEPENG | reporter.nih.gov |
| Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,831,134 | June 1, 2020 | June 30, 2024 | CHAN, ANDREW T | reporter.nih.gov |
| Evaluating a remotely delivered, digital health CRC screening intervention among rural patients of a community health center | NIH | National Cancer Institute | 2023 to 2025 | $1,824,412 | August 1, 2023 | July 31, 2028 | FRERICHS, LEAH M. | reporter.nih.gov |
| Role of the complement C3a receptor on immune and non immune intestinal barrier functions and microbiota in colorectal cancer development | NIH | National Cancer Institute | 2022 to 2025 | $1,824,040 | August 1, 2022 | July 31, 2027 | GUGLIETTA, SILVIA | reporter.nih.gov |
| The role of ACSS2 in colon cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,822,535 | April 1, 2022 | March 31, 2027 | WOTTON, DAVID | reporter.nih.gov |
| Epigenetic dysregulation in APC-negative colorectal cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,815,653 | August 1, 2020 | December 31, 2025 | ELLIS, NATHAN A. | reporter.nih.gov |
| Harnessing the power of p53 with Panaxynol from American Ginseng to suppress colitis and prevent colon cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,813,414 | January 1, 2020 | December 31, 2024 | HOFSETH, LORNE J | reporter.nih.gov |
| Use of radioprotector in rectal cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,812,623 | April 8, 2022 | January 31, 2028 | OBERLEY-DEEGAN, REBECCA E | reporter.nih.gov |
| Molecular mechanisms of modular nuclease domains | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,812,290 | September 15, 2021 | August 31, 2026 | MANHART, CAROL M | reporter.nih.gov |
| Biological determinants of colorectal cancer outcomes in Latinos of diverseýancestral origins | NIH | National Cancer Institute | 2021 to 2024 | $1,811,473 | May 1, 2021 | April 30, 2025 | SCHMIT, STEPHANIE L. | reporter.nih.gov |
| Mechanisms of nuclear Mcl-1 mediated chemoresistance | NIH | National Cancer Institute | 2021 to 2025 | $1,808,294 | December 4, 2020 | November 30, 2025 | MELENHORST, JAN J | reporter.nih.gov |
| Effects of Aerobic Exercise on Skeletal Muscle Remodeling in Colon Cancer | NIH | National Cancer Institute | 2022 to 2024 | $1,797,544 | June 3, 2022 | February 28, 2025 | BROWN, JUSTIN C | reporter.nih.gov |
| The role of HIF2alpha in colon carcinogenesis | NIH | National Cancer Institute | 2021 to 2025 | $1,782,443 | July 6, 2010 | June 30, 2026 | SHAH, YATRIK M | reporter.nih.gov |
| A Chemical Genetic Approach to Exploring Novel Therapeutic Space for Colorectal Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,782,261 | June 1, 2023 | February 28, 2026 | DAR, ARVIN | reporter.nih.gov |
| Targeting Tryptophan Metabolism in Rectal Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,780,760 | September 21, 2023 | August 31, 2028 | CIORBA, MATTHEW AARON | reporter.nih.gov |
| Physiological and psychosocial aspects of reproductive health after early-onset colorectal cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,773,238 | May 11, 2023 | April 30, 2028 | HOLOWATYJ, ANDREANA NATALIE | reporter.nih.gov |
| Safety and Efficacy Trial of the ColoSeal ICD System for the Treatment of Rectal Cancer Patients | NIH | National Cancer Institute | 2024 to 2025 | $1,767,129 | September 20, 2024 | August 31, 2026 | FONG, KENTON DODYAN | reporter.nih.gov |
| Bayesian Network-Based Integrative Genomics Methods for Precision Medicine | NIH | National Cancer Institute | 2021 to 2024 | $1,760,765 | February 1, 2021 | January 31, 2026 | MORRIS, JEFFREY S | reporter.nih.gov |
| Allosteric inhibitors targeting oncogenic BRAF V600E dimers | NIH | National Cancer Institute | 2021 to 2024 | $1,760,127 | December 1, 2019 | November 30, 2024 | GAVATHIOTIS, EVRIPIDIS | reporter.nih.gov |
| Immunoepigenetic targeting of MHC regulators in FAP | NIH | National Cancer Institute | 2023 to 2025 | $1,755,233 | April 1, 2023 | March 31, 2028 | DASHWOOD, RODERICK H | reporter.nih.gov |
| Understanding the Mechanism of a Gut Microbial Genotoxin Involved in Colorectal Carcinogenesis | NIH | National Cancer Institute | 2021 to 2025 | $1,752,081 | July 1, 2016 | January 31, 2027 | BALSKUS, EMILY PATRICIA | reporter.nih.gov |
| Development of an automated, point of care DNA methylation cartridge blood test for colorectal cancer detection in LMICs- an academic-industrial partnership | NIH | National Cancer Institute | 2023 to 2025 | $1,730,278 | June 6, 2023 | May 31, 2028 | SUKUMAR, SARASWATI | reporter.nih.gov |
| Personalized Risk-AdaptIve Surveillance (PRAISE) - Implications of Algorithmic Bias | NIH | National Cancer Institute | 2021 to 2024 | $1,727,788 | September 1, 2018 | August 31, 2026 | BANSAL, AASTHAA | reporter.nih.gov |
| Reducing Colorectal Cancer Health Disparities: An mHealth Intervention to Improve Screening among African American Men | NIH | National Cancer Institute | 2021 to 2024 | $1,724,375 | September 11, 2019 | June 30, 2025 | LEAF, SAMANTHA L. | reporter.nih.gov |
| Nanodelivery of FP polymers to improve treatment of metastatic colorectal cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,721,807 | July 1, 2023 | June 30, 2028 | GMEINER, WILLIAM H. | reporter.nih.gov |
| Targeting Lipid Metabolism in Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,709,510 | April 1, 2021 | March 31, 2027 | ZAYTSEVA, YEKATERINA | reporter.nih.gov |
| Regulation of CD8+T cells by Zbtb42 | NIH | National Cancer Institute | 2022 to 2025 | $1,705,648 | September 1, 2022 | August 31, 2027 | POOJARY, VENUPRASAD K | reporter.nih.gov |
| NR4A1 Antagonists Inhibit Colorectal Cancer Growth and Enhance Immune Surveillance | NIH | National Cancer Institute | 2023 to 2025 | $1,700,667 | January 1, 2023 | December 31, 2026 | SAFE, STEPHEN H. | reporter.nih.gov |
| Development of an NTSR1-Targeted Radiotherapeutic for Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,691,139 | April 1, 2021 | March 31, 2027 | GARRISON, JERED C | reporter.nih.gov |
| I-SCREEN: Increasing Screening for Cancer using a Randomized Evaluation of EHR-based Nudges | NIH | National Institute on Aging | 2022 to 2024 | $1,679,739 | August 15, 2020 | August 31, 2025 | NAVATHE, AMOL S | reporter.nih.gov |
| Oxidative pentose phosphate pathway regulates AMPK homeostasis by balancing opposing LKB1 and PP2A | NIH | National Cancer Institute | 2021 to 2024 | $1,679,559 | April 15, 2014 | February 28, 2025 | CHEN, JING | reporter.nih.gov |
| Identifying the mechanism of anti-colorectal immunity induced by mucoinvasive colonic bacteria | NIH | National Cancer Institute | 2023 to 2025 | $1,677,626 | December 1, 2022 | November 30, 2027 | HAND, TIMOTHY WESLEY | reporter.nih.gov |
| Molecular and Epigenetic Control of Wnt/b-catenin-mediated oncogenesis by KDM4B | NIH | National Cancer Institute | 2021 to 2024 | $1,675,571 | February 1, 2020 | January 31, 2025 | WANG, CUN-YU | reporter.nih.gov |
| Immune determinants modulating cancer development in Lynch Syndrome | NIH | National Cancer Institute | 2024 to 2025 | $1,672,056 | June 15, 2024 | May 31, 2026 | BHARDWAJ, NINA | reporter.nih.gov |
| IGFBP1 mediates a liver-bone-muscle axis in colorectal cancer cachexia | NIH | National Institute of Arthritis and Musculoskeletal and Skin Diseases | 2022 to 2025 | $1,650,159 | September 1, 2022 | July 31, 2027 | BONETTO, ANDREA | reporter.nih.gov |
| Novel synthetic lethality strategy for TP53 mutant colorectal cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,631,453 | August 10, 2023 | July 31, 2027 | FOUNTZILAS, CHRISTOS | reporter.nih.gov |
| Interpretable deep learning models for translational medicine Renewal | NIH | National Library of Medicine | 2021 to 2025 | $1,626,752 | April 1, 2015 | May 31, 2028 | LU, XINGHUA | reporter.nih.gov |
| Regulation of DGAT - dependent lipogenesis in colonic epithelial growth | NIH | National Cancer Institute | 2021 to 2025 | $1,619,709 | April 1, 2021 | June 30, 2026 | SAVKOVIC, SUZANA D. | reporter.nih.gov |
| Role of Circadian Factors in Inflammation and Colorectal Adenoma Risk | NIH | National Cancer Institute | 2021 to 2024 | $1,602,654 | September 11, 2019 | August 31, 2025 | BURCH, JAMES | reporter.nih.gov |
| Novel TYRO3 inhibitors for treatment of cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,600,201 | April 1, 2021 | March 31, 2027 | WANG, XIAODONG | reporter.nih.gov |
| Surgery triggered immune response and liver metastases | NIH | National Cancer Institute | 2022 to 2025 | $1,581,913 | January 1, 2018 | March 31, 2028 | TSUNG, ALLAN | reporter.nih.gov |
| Defining the Function of Age-Related Epimutation in Intestinal Tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $1,579,721 | August 8, 2019 | July 31, 2030 | SHEN, LANLAN | reporter.nih.gov |
| Patient-Centered Reminders to Inform, Motivate, and Engage Colorectal Cancer Screening Adherence in Rural Communities: The PRIME-CRC Trial | NIH | National Cancer Institute | 2021 to 2024 | $1,579,255 | June 1, 2020 | May 31, 2026 | ARNOLD, CONNIE L. | reporter.nih.gov |
| Role of innate immunity and the microbiome in colitis-associated dysplasia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,577,776 | September 1, 2014 | April 30, 2027 | ABREU, MARIA TERESA | reporter.nih.gov |
| Strategies for Optimizing a Mailed FIT Program in Appalachia | NIH | National Cancer Institute | 2023 to 2025 | $1,574,752 | August 28, 2023 | July 31, 2028 | REITER, PAUL L | reporter.nih.gov |
| Fatty acids and their receptors-mediated tumor metastasis and progression | NIH | National Cancer Institute | 2021 to 2024 | $1,574,167 | February 14, 2020 | January 31, 2026 | YU, HUA E | reporter.nih.gov |
| Multi-site Gastrointestinal Cancer Detection by Stool DNA Methylation | NIH | National Cancer Institute | 2021 to 2024 | $1,573,848 | April 1, 2023 | March 31, 2025 | KISIEL, JOHN | reporter.nih.gov |
| Znf740 in the regulation of CD8+T cell exhaustion | NIH | National Cancer Institute | 2023 to 2025 | $1,563,506 | September 1, 2023 | August 31, 2028 | POOJARY, VENUPRASAD K | reporter.nih.gov |
| Geriatric assessment domains in relation to treatment outcomes among older adults with colorectal cancer | NIH | National Institute on Aging | 2024 to 2025 | $1,562,259 | July 15, 2024 | March 31, 2029 | HARDIKAR, SHEETAL | reporter.nih.gov |
| ST8Sia6 expression on tumors inhibits the immune response | NIH | National Cancer Institute | 2021 to 2024 | $1,561,669 | December 1, 2019 | November 30, 2024 | SHAPIRO, VIRGINIA SMITH | reporter.nih.gov |
| Role of the Epitranscriptome in Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,560,410 | August 1, 2019 | July 31, 2026 | GREGORY, RICHARD I. | reporter.nih.gov |
| The Role of PHLPP in Colon Cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,552,740 | April 1, 2009 | April 30, 2026 | GAO, TIANYAN | reporter.nih.gov |
| An ensemble deep learning model for tumor bud detection and risk stratification in colorectal carcinoma. | NIH | National Cancer Institute | 2023 to 2025 | $1,550,974 | July 1, 2023 | June 30, 2028 | CHEN, WEI | reporter.nih.gov |
| Cholesterol metabolism in mesenchymal colorectal cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,543,273 | December 9, 2022 | November 30, 2027 | MOSCAT, JORGE | reporter.nih.gov |
| The Development of First-in-Class Inhibitors of Oncogenic CHD1L for the Treatment of Colorectal Cancer. | NIH | National Cancer Institute | 2021 to 2024 | $1,530,498 | August 1, 2020 | April 30, 2026 | LABARBERA, DANIEL V. | reporter.nih.gov |
| A novel, transferable sialylation-mediated mechanism of chemoradioresistance in GI cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,527,409 | February 1, 2022 | January 31, 2027 | HARDIMAN, KARIN MARIE | reporter.nih.gov |
| MicroRNA control of tumor-promoting inflammation in colon cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,518,283 | February 8, 2022 | January 31, 2027 | GOPAL, MURUGAIYAN | reporter.nih.gov |
| Molecular Mechanisms of Fructose-induced Colorectal Cancer Cell Survival | NIH | National Cancer Institute | 2022 to 2024 | $1,515,840 | January 10, 2022 | May 31, 2024 | GONCALVES, MARCUS DASILVA | reporter.nih.gov |
| Impact of fasting on intestinal stem cells and cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,507,842 | September 1, 2020 | May 31, 2025 | YILMAZ, OMER | reporter.nih.gov |
| Exploiting the distinct genomics and signaling of colorectal cancers to effectively target ERK | NIH | National Cancer Institute | 2021 to 2024 | $1,502,540 | December 10, 2018 | November 30, 2024 | YAEGER, RONA | reporter.nih.gov |
| Cancer in Your Community: Strategies to Reduce Cancer and Chronic Disease in the Arkansas Delta | NIH | Office of the Director, National Institutes of Health | 2023 to 2024 | $1,499,585 | September 21, 2023 | April 7, 2025 | MITCHELL, TRENA | reporter.nih.gov |
| Colorectal Cancer Screening with Optical Coherence Tomography | NIH | National Cancer Institute | 2024 to 2025 | $1,482,339 | August 1, 2024 | July 31, 2029 | TEARNEY, GUILLERMO J | reporter.nih.gov |
| Determining the structural- and functional-level effects of diet-specific interventions on the gut microbiota of a diverse sample of Southern United States adults | NIH | National Cancer Institute | 2021 to 2025 | $1,479,557 | June 1, 2021 | May 31, 2026 | CARSON, TIFFANY LASHAUN | reporter.nih.gov |
| Characterization and targeting of rapid nucleotide exchange RAS mutations | NIH | National Cancer Institute | 2021 to 2024 | $1,473,768 | March 1, 2020 | February 28, 2025 | WESTOVER, KENNETH | reporter.nih.gov |
| Targeting SUMO1 degradation for advanced colon cancer therapy | NIH | National Cancer Institute | 2022 to 2025 | $1,470,853 | July 1, 2022 | June 30, 2027 | BELLAIL, ANITA | reporter.nih.gov |
| Randomized controlled trial of the stool DNA test to improve colorectal cancer screening among Alaska Native people | NIH | National Cancer Institute | 2021 to 2024 | $1,453,189 | April 1, 2020 | August 31, 2025 | REDWOOD, DIANA | reporter.nih.gov |
| Reactivation of type I interferon pathway to increase the efficacy of chemotherapy | NIH | National Cancer Institute | 2021 to 2024 | $1,453,040 | March 3, 2020 | February 28, 2025 | FUCHS, SERGE Y | reporter.nih.gov |
| Couple Communication in Cancer: A Multi-Method Examination - Renewal - 1 | NIH | National Cancer Institute | 2024 to 2025 | $1,448,909 | September 20, 2016 | August 31, 2029 | LANGER, SHELBY | reporter.nih.gov |
| Wnt signaling in obesity-associated colorectal cancer | NIH | National Cancer Institute | 2022 to 2025 | $1,447,372 | May 23, 2022 | February 28, 2027 | ROPER, JATIN | reporter.nih.gov |
| The role of long noncoding RNA CRNDE in normal physiology and cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,444,226 | June 1, 2023 | May 31, 2028 | MENDELL, JOSHUA T | reporter.nih.gov |
| Understanding how heme and iron are metabolized by anaerobic commensal bacteria and host-microbiome communities | NIH | National Institute of General Medical Sciences | 2021 to 2025 | $1,426,148 | May 1, 2020 | February 28, 2026 | DUBOIS, JENNIFER L | reporter.nih.gov |
| Stimulating Lymphocyte Activation Combined with Inhibition of Immunosuppressive Signals in Colon Cancer Metastases | NIH | National Cancer Institute | 2022 to 2025 | $1,423,726 | January 22, 2020 | December 31, 2026 | MAKER, AJAY V. | reporter.nih.gov |
| Targeting Translation Dependence in Colorectal Cancer Progression | NIH | National Cancer Institute | 2021 to 2024 | $1,420,797 | April 1, 2013 | November 30, 2025 | SHE, QING-BAI | reporter.nih.gov |
| Rational translation of gold nanoparticle mediated radiosensitization to the clinic | NIH | National Cancer Institute | 2023 to 2025 | $1,412,352 | January 13, 2021 | December 31, 2026 | KRISHNAN, SUNIL | reporter.nih.gov |
| Refined Capture-Recapture Methods for Surveilling Cancer Recurrence | NIH | National Cancer Institute | 2022 to 2025 | $1,402,863 | September 20, 2022 | August 31, 2026 | LYLES, ROBERT H | reporter.nih.gov |
| p38gamma MAPK signaling promotes intestinal tumorigenesis | NIH | National Cancer Institute | 2021 to 2025 | $1,395,284 | June 15, 2020 | May 31, 2026 | CHEN, GUAN | reporter.nih.gov |
| Body composition and adiposity-associated thromboinflammation in colorectal cancer prognosis | NIH | National Cancer Institute | 2024 to 2025 | $1,388,285 | May 1, 2024 | April 30, 2028 | BYRD, DORATHA ARMENTHUS | reporter.nih.gov |
| DNA Damage Repair by MUTYH and MUTYH Variants Associated with Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,387,699 | July 15, 1995 | June 30, 2027 | DAVID, SHEILA SUE | reporter.nih.gov |
| Addressing challenges in colorectal cancer risk prediction | NIH | National Cancer Institute | 2024 to 2025 | $1,385,791 | June 7, 2024 | May 31, 2028 | NELSON, KERRIE P | reporter.nih.gov |
| A microengineered colon cancer-chip designed to investigate tumor-stromal interactions driving cancer progression | NIH | National Cancer Institute | 2022 to 2025 | $1,384,529 | December 1, 2021 | November 30, 2026 | MUMENTHALER, SHANNON MICHELLE | reporter.nih.gov |
| Elucidating the role of transcriptomics in driving ethnicity and ancestry-related disparities in colorectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,384,221 | April 1, 2024 | March 31, 2029 | FIGUEIREDO, JANE C. | reporter.nih.gov |
| Tumor-Targeted Multimodality Nanoscale Coordination Polymers for Chemo-Immunotherapy of Metastatic Colorectal Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,377,117 | March 1, 2023 | February 29, 2028 | WEICHSELBAUM, RALPH R | reporter.nih.gov |
| Evaluating and Optimizing Novel nSMase2 Inhibitors in the Treatment of Cancers | NIH | National Cancer Institute | 2024 to 2025 | $1,375,950 | September 1, 2024 | August 31, 2029 | BLELLOCH, ROBERT | reporter.nih.gov |
| Targeting ß-TrCP regulators to improve CRC response to chemotherapy | NIH | National Cancer Institute | 2024 to 2025 | $1,375,343 | March 5, 2024 | February 28, 2029 | SPIEGELMAN, VLADIMIR S. | reporter.nih.gov |
| Semi-supervised Approaches to Denoising Electronic Health Records Data for Risk Prediction | NIH | National Library of Medicine | 2021 to 2024 | $1,374,026 | August 1, 2021 | April 30, 2026 | CAI, TIANXI | reporter.nih.gov |
| Defining the mechanism of inositol 1,4,5-triphosphate receptor-mediated metastatic liver colonization in colorectal cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,373,770 | September 21, 2021 | August 31, 2026 | MOY, RYAN | reporter.nih.gov |
| mHealth Navigation using SMS Texting to Improve Colorectal Cancer Screening Among Homeless Persons | NIH | National Institute on Minority Health and Health Disparities | 2025 | $1,372,725 | September 19, 2025 | June 30, 2027 | ASGARY, RAMIN | reporter.nih.gov |
| FITting noninvasive testing into Lynch syndrome colorectal cancer surveillance: a multicenter, prospective trial | NIH | National Cancer Institute | 2024 to 2025 | $1,371,823 | September 5, 2024 | August 31, 2029 | KUPFER, SONIA | reporter.nih.gov |
| Nutrigenomics of Intestinal Vitamin D Action | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,369,028 | July 5, 2017 | March 31, 2028 | CHRISTAKOS, SYLVIA S | reporter.nih.gov |
| Interrogating the Role of Bacterial Methyl-modifying Enzymes in Pathoadaptation and Host Epigenetic Interference in Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,368,607 | August 5, 2024 | July 31, 2029 | JOHNSTON, CHRISTOPHER D | reporter.nih.gov |
| Cytokine-mediated regulation of immunity and microenvironment in colorectal cancer metastasis | NIH | National Cancer Institute | 2024 to 2025 | $1,363,074 | January 9, 2024 | December 31, 2028 | GRIVENNIKOV, SERGEI I | reporter.nih.gov |
| Personalizing genetic test results management and outcomes after diagnosis of cancer: the Georgia-California SEER Genelink Study | NIH | National Cancer Institute | 2024 to 2025 | $1,362,587 | March 5, 2024 | February 28, 2029 | KURIAN, ALLISON W. | reporter.nih.gov |
| Harnessing DNA methylation in peripheral blood for improved colorectal cancer prevention | NIH | National Cancer Institute | 2024 to 2025 | $1,359,876 | August 1, 2024 | July 31, 2028 | SONG, MINGYANG | reporter.nih.gov |
| Methodologic Innovations in Cancer Epidemiology | NIH | National Cancer Institute | 2023 to 2025 | $1,359,433 | March 1, 2023 | February 28, 2027 | ROSNER, BERNARD A | reporter.nih.gov |
| Early detection of colorectal cancer in the traditional and serrated pathways | NIH | National Cancer Institute | 2021 to 2024 | $1,349,852 | September 1, 2020 | August 31, 2025 | WANG, THOMAS D | reporter.nih.gov |
| Gain-of-function mutant p53 and metabolic reprogramming in colorectal cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,346,662 | April 1, 2021 | March 31, 2027 | HU, WENWEI | reporter.nih.gov |
| Defining the role of seed and soil in peritoneal metastasis evolution | NIH | National Cancer Institute | 2024 to 2025 | $1,343,975 | May 1, 2024 | April 30, 2029 | NAXEROVA, KAMILA | reporter.nih.gov |
| Implementing multilevel colon cancer screening interventions to reduce rural cancer disparities | NIH | National Cancer Institute | 2021 to 2024 | $1,343,441 | July 15, 2019 | June 30, 2025 | JAMES, AIMEE S | reporter.nih.gov |
| Mechanisms of Serrated Colon Tumor Suppression | NIH | National Cancer Institute | 2023 to 2025 | $1,339,086 | June 8, 2023 | May 31, 2028 | VERZI, MICHAEL P. | reporter.nih.gov |
| Assessment of hyperthermia-based multimodal approach for hepatic colorectal metastases | NIH | National Cancer Institute | 2023 to 2025 | $1,326,934 | September 19, 2023 | July 31, 2028 | LEE, YONG JUN | reporter.nih.gov |
| Expanding access to colorectal cancer screening through community pharmacies: The PharmFIT study | NIH | National Cancer Institute | 2024 to 2025 | $1,316,228 | February 1, 2024 | January 31, 2029 | BRENNER, ALISON T | reporter.nih.gov |
| Role for myeloid acid ceramidase in colon inflammation and cancer | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $1,315,037 | April 1, 2022 | March 31, 2027 | SNIDER, ASHLEY JONES | reporter.nih.gov |
| Advanced Colonoscopy Training Developed Through Manikin Sensorization and Computational Optimization Modeling | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $1,314,913 | July 1, 2023 | April 30, 2027 | MOORE, JASON ZACHARY | reporter.nih.gov |
| Randomized Trial to Improve Care of Patients with Hereditary Cancer Syndromes | NIH | National Cancer Institute | 2024 to 2025 | $1,314,067 | April 1, 2024 | March 31, 2029 | O'CONNOR, PATRICK J | reporter.nih.gov |
| Epithelial adherens junctions regulate colon cell behavior through RNAi and lncRNAs | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $1,314,045 | March 26, 2021 | February 28, 2026 | KOURTIDIS, ANTONIS | reporter.nih.gov |
| Nanoscale Coordination Polymers of Cyclic-di-nucleotides and Peptide Antigens for Effective Therapy of Metastatic Colorectal Cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,313,375 | June 1, 2023 | May 31, 2028 | WEICHSELBAUM, RALPH R | reporter.nih.gov |
| Immunomodulatory Effects of Targeting DNA Repair with Novel Temozolomide Combinations in Colorectal Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,304,790 | August 5, 2021 | September 30, 2026 | CECCHINI, MICHAEL | reporter.nih.gov |
| Development of blood-based methylation biomarkers for CRC risk prediction | NIH | National Cancer Institute | 2023 to 2025 | $1,300,887 | September 20, 2023 | August 31, 2028 | GHOSH, JAYASHRI | reporter.nih.gov |
| Predicting neoadjuvant treatment response of locally advanced rectal cancer using co-registered endo-rectal photoacoustic and ultrasound imaging | NIH | National Institute of Biomedical Imaging and Bioengineering | 2023 to 2025 | $1,298,022 | May 1, 2023 | April 30, 2027 | ZHU, QUING | reporter.nih.gov |
| Translational Science of Gastrointestinal Cancer Initiation and Progression | NIH | National Cancer Institute | 2021 to 2025 | $1,289,608 | September 19, 2018 | August 31, 2028 | YU, MING | reporter.nih.gov |
| Roles for Intracellular pH Dynamics in Cancer | NIH | National Cancer Institute | 2021 to 2025 | $1,284,345 | June 1, 2016 | March 31, 2028 | BARBER, DIANE L | reporter.nih.gov |
| Biology of R-Spondin-Induced Sensitization to Asparaginase in Colorectal Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,282,528 | August 1, 2021 | July 31, 2027 | GUTIERREZ, ALEJANDRO | reporter.nih.gov |
| MS4A7 in tumor resistance to immunotherapy | NIH | National Cancer Institute | 2024 to 2025 | $1,281,774 | March 5, 2024 | February 28, 2029 | ZOU, WEIPING | reporter.nih.gov |
| Single-molecule nanopore-based identification of methylome signatures in cfDNA for early colorectal cancer detection | NIH | National Cancer Institute | 2024 to 2025 | $1,280,475 | September 1, 2024 | August 31, 2029 | JI, HANLEE P | reporter.nih.gov |
| BET degraders for improving colorectal cancer therapy | NIH | National Cancer Institute | 2023 to 2025 | $1,279,978 | October 9, 2023 | March 31, 2027 | ZHANG, LIN | reporter.nih.gov |
| Targeting GARP-TGFbeta for Immunotherapy of Non-Small Cell Lung Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,273,521 | September 1, 2024 | August 31, 2029 | LI, ZIHAI | reporter.nih.gov |
| Mechanisms of DNA methylation signaling and dysregulation in colon cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,264,638 | July 2, 2024 | June 30, 2029 | ROTHBART, SCOTT | reporter.nih.gov |
| A magnetic capsule endoscope for colonoscopy in patients with inflammatory bowel disease | NIH | National Institute of Biomedical Imaging and Bioengineering | 2021 to 2024 | $1,258,230 | September 18, 2014 | December 31, 2025 | OBSTEIN, KEITH L | reporter.nih.gov |
| MGH- PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors | NIH | National Cancer Institute | 2024 to 2025 | $1,257,849 | May 1, 2024 | April 30, 2026 | CHAN, ANDREW T | reporter.nih.gov |
| Defining the landscape of bacterial-colonized microniches in tumors and their role in intratumoral heterogeneity. | NIH | National Cancer Institute | 2024 to 2025 | $1,247,680 | September 1, 2024 | August 31, 2029 | BULLMAN, SUSAN | reporter.nih.gov |
| Bacteria-derived xenobiotics in colon cancer prevention: Link to GPR109A and colonic ketogenesis | NIH | National Cancer Institute | 2023 to 2025 | $1,247,181 | July 7, 2023 | June 30, 2028 | THANGARAJU, MUTHUSAMY | reporter.nih.gov |
| Project Title: Low-dose erlotinib and mesalamine for prevention of colitis-associated colorectal cancer (CAC) | NIH | National Cancer Institute | 2024 to 2025 | $1,246,808 | September 25, 2025 | March 24, 2027 | VILAR SANCHEZ, EDUARDO | reporter.nih.gov |
| Interrogating the role of arachidonic acid metabolism in modulating the tumor immune microenvironment as a novel path to therapeutic intervention | NIH | National Cancer Institute | 2024 to 2025 | $1,246,745 | September 6, 2024 | August 31, 2029 | YEATMAN, TIMOTHY J | reporter.nih.gov |
| Aspirins legacy on cancer and overall benefit: risk balance over a 15-year horizon | NIH | National Cancer Institute | 2024 to 2025 | $1,238,913 | September 26, 2024 | August 31, 2029 | WARNER, ERICA T | reporter.nih.gov |
| Investigating the contribution of cellular senescence to the efficacy of radiation therapy. | NIH | National Cancer Institute | 2021 to 2025 | $1,237,994 | September 1, 2021 | August 31, 2026 | ROMESSER, PAUL BERNARD | reporter.nih.gov |
| Evaluating a Multilevel Intervention to Increase Colonoscopic Follow-up after Abnormal Stool-based Colorectal Cancer Screening in a Community Safety-Net Setting | NIH | National Cancer Institute | 2024 to 2025 | $1,230,397 | September 5, 2024 | August 31, 2029 | MAY, FOLASADE POPOOLA | reporter.nih.gov |
| PB-iCRC: Multi-site Practice-Based Implementation of a ColoRectal Cancer screening intervention | NIH | National Cancer Institute | 2024 to 2025 | $1,229,626 | May 10, 2024 | April 30, 2029 | LEMASTER, JOSEPH W | reporter.nih.gov |
| The regulation of mutant p53 protein accumulation in cancer: molecular basis and therapeutic potential | NIH | National Cancer Institute | 2023 to 2025 | $1,225,741 | July 1, 2021 | June 30, 2027 | FENG, ZHAOHUI | reporter.nih.gov |
| MTGs in Intestinal Biology and Injury Responses | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,223,368 | July 1, 2024 | May 31, 2028 | WILLIAMS, CHRISTOPHER S. | reporter.nih.gov |
| Elucidating the role and mechanisms by which collagenase producing intestinal bacteria promote colorectal cancer recurrence and metastasis following surgery. | NIH | National Cancer Institute | 2021 to 2025 | $1,208,495 | January 1, 2021 | December 31, 2025 | SHOGAN, BENJAMIN | reporter.nih.gov |
| LIN28B promotes colorectal cancer differentiation and metastasis | NIH | National Cancer Institute | 2023 to 2025 | $1,202,020 | March 1, 2000 | March 31, 2028 | RUSTGI, ANIL K | reporter.nih.gov |
| Acceptance and Commitment Therapy for Patient Fatigue Interference and Caregiver Burden in Advanced Gastrointestinal Cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,199,980 | May 1, 2024 | April 30, 2029 | MOSHER, CATHERINE E | reporter.nih.gov |
| The lysosomal fasting response in intestinal stem cells and cancer | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $1,198,646 | August 15, 2024 | June 30, 2028 | YILMAZ, OMER | reporter.nih.gov |
| Safety and Efficacy Trial of the ColoSeal ICD System for the Treatment of Diverticular Disease Patients | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $1,192,362 | September 19, 2025 | August 31, 2027 | FONG, KENTON DODYAN | reporter.nih.gov |
| Targeting the Sam68-stimulated PARP1 activation for cancer treatment | NIH | National Cancer Institute | 2021 to 2025 | $1,190,833 | June 1, 2020 | October 1, 2025 | WAN, FENGYI | reporter.nih.gov |
| Transfer RNA sequencing and application to cancer research and clinics | NIH | National Cancer Institute | 2022 to 2024 | $1,187,465 | September 15, 2022 | August 31, 2025 | PAN, TAO | reporter.nih.gov |
| A highly sensitive linear amplification based DNA methylation profiling technique for clinical cancer research | NIH | National Cancer Institute | 2022 to 2024 | $1,181,771 | June 8, 2022 | May 31, 2026 | CHIU, BRIAN C-H | reporter.nih.gov |
| Targeting the Immunosuppressive Tumor Microenvironment for Colorectal Cancer Treatment | NIH | National Cancer Institute | 2023 to 2025 | $1,180,814 | September 1, 2023 | August 31, 2028 | WANG, QINGDING | reporter.nih.gov |
| Using Natural Language Processing and Crowdsourcing to Monitor and Evaluate Public Information and Communication Disparities about Colon Cancer Screening | NIH | National Cancer Institute | 2023 to 2025 | $1,174,537 | April 15, 2021 | February 28, 2027 | KING, ANDY J | reporter.nih.gov |
| Assessing the long-term impacts of the COVID-19 pandemic on disparities in cancer screening and follow-up (RESTORE) | NIH | National Cancer Institute | 2024 to 2025 | $1,174,468 | July 15, 2021 | June 30, 2027 | CORONADO, GLORIA D. | reporter.nih.gov |
| The oral-gut axis in colorectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,161,644 | March 1, 2024 | February 28, 2029 | KAMADA, NOBUHIKO | reporter.nih.gov |
| Expanding cancer research capacity in Nigeria with team science | NIH | National Cancer Institute | 2022 to 2025 | $1,160,841 | March 8, 2022 | February 28, 2027 | KINGHAM, T PETER | reporter.nih.gov |
| muMS2: an open source R package for analyzing and integrating multi-omics datasets to improve early detection and understanding of colorectal cancer | NIH | National Cancer Institute | 2022 to 2024 | $1,150,435 | June 1, 2022 | May 31, 2025 | SCHLOSS, PATRICK DAVID | reporter.nih.gov |
| Three-Dimensional Multi-Parametric Ultrasound for Monitoring Therapy of Liver Metastasis | NIH | National Cancer Institute | 2023 to 2025 | $1,150,411 | April 1, 2016 | February 28, 2027 | EL KAFFAS, AHMED | reporter.nih.gov |
| Study of PTPRF-Mediated Regulation of Wnt Signaling | NIH | National Institute of General Medical Sciences | 2023 to 2025 | $1,133,508 | June 1, 2023 | March 31, 2027 | GAO, TIANYAN | reporter.nih.gov |
| International Study of Subsequent Colorectal Cancer Among Survivors of Childhood, Adolescent, and Young Adult Cancers (I-SCRY) | NIH | National Cancer Institute | 2022 to 2024 | $1,132,151 | February 8, 2022 | January 31, 2026 | MOSKOWITZ, CHAYA | reporter.nih.gov |
| A Pragmatic Randomized Controlled Trial to Evaluate the Effectiveness of an Intervention to Promote Guideline-Concordant Colorectal Cancer Surveillance | NIH | National Cancer Institute | 2024 to 2025 | $1,122,732 | August 1, 2024 | July 31, 2029 | VEENSTRA, CHRISTINE | reporter.nih.gov |
| Functional and molecular characterization of Oncofetal Stem Cells in CRC | NIH | National Cancer Institute | 2024 to 2025 | $1,120,594 | September 1, 2024 | August 31, 2029 | MZOUGHI, SLIM | reporter.nih.gov |
| Duloxetine to Prevent Oxaliplatin-Induced Chemotherapy-Induced Peripheral Neuropathy: A Randomized, Double-Blind, Placebo-Controlled Phase II to Phase III Study | NIH | National Cancer Institute | 2021 to 2024 | $1,106,695 | January 10, 2019 | December 31, 2025 | SMITH, ELLEN MARY LAVOIE | reporter.nih.gov |
| A20 and Tumor Immune Responses | NIH | National Cancer Institute | 2024 to 2025 | $1,105,779 | August 1, 2024 | July 31, 2026 | MA, AVERIL I | reporter.nih.gov |
| Organoid modeling to determine and reverse age-related epigenetic changes contributing to risk of colorectal cancer | NIH | National Cancer Institute | 2021 to 2024 | $1,104,519 | July 1, 2019 | December 31, 2024 | BAYLIN, STEPHEN B. | reporter.nih.gov |
| Molecular mechanisms of developmental reprogramming in colorectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,103,696 | September 1, 2024 | August 31, 2029 | SETHI, NILAY | reporter.nih.gov |
| MRI and blood biomarkers of neoadjuvant therapy response and outcomes in rectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,098,438 | February 1, 2024 | January 31, 2029 | LI, RUIJIANG | reporter.nih.gov |
| Sulindac sensitizes colorectal cancer to anti-PD-L1 therapy | NIH | National Cancer Institute | 2023 to 2024 | $1,096,423 | August 1, 2023 | July 31, 2027 | XI, YAGUANG | reporter.nih.gov |
| ROLE OF SORD IN SUGAR-MEDIATED CANCER METASTASIS | NIH | National Cancer Institute | 2022 to 2025 | $1,087,515 | March 8, 2022 | February 28, 2028 | YUN, JIHYE | reporter.nih.gov |
| Armed nanobodies as anti-infectives and anti-tumor agents | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,085,800 | July 19, 2024 | May 31, 2029 | WU, HAO | reporter.nih.gov |
| Hereditary Cancer Variants of Uncertain Significance in Stem Cells | NIH | National Cancer Institute | 2021 to 2024 | $1,085,466 | April 4, 2019 | March 31, 2026 | HEINEN, CHRISTOPHER D. | reporter.nih.gov |
| Systematic liquid biopsy to monitor residual disease and treatment efficacy in gastrointestinal cancer patients | NIH | National Cancer Institute | 2022 to 2025 | $1,079,955 | September 5, 2022 | June 30, 2027 | PARIKH, APARNA RAJ | reporter.nih.gov |
| Engineering S. typhimurium for metastatic colorectal cancer | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2024 | $1,060,835 | June 15, 2020 | November 30, 2025 | DANINO, TAL | reporter.nih.gov |
| A 4D-tunable hydrogel for the study of the impact of the tumor microenvironment on the development of colorectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,050,192 | July 1, 2024 | June 30, 2029 | ALLBRITTON, NANCY L. | reporter.nih.gov |
| Towards a complete characterization of the metastasis founder clones in colorectal cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,046,031 | July 1, 2023 | December 31, 2028 | NAXEROVA, KAMILA | reporter.nih.gov |
| Automated Colorectal Cancer Educational Support System (ACCESS): Development and Validation of a Novel Online Decision Aid for Improving Colorectal Cancer Screening Uptake | NIH | National Cancer Institute | 2021 to 2024 | $1,043,808 | July 1, 2020 | June 30, 2026 | ALMARIO, CHRISTOPHER V | reporter.nih.gov |
| Assessing residential neighborhood exposome exposures and the associations with cancer incidence | NIH | National Cancer Institute | 2023 to 2025 | $1,035,844 | July 8, 2023 | June 30, 2028 | PERERA, ROBERT ANTHONY | reporter.nih.gov |
| A vascularized microphysiological system (MPS) platform for modeling peritoneal carcinomatosis | NIH | National Cancer Institute | 2024 to 2025 | $1,022,846 | June 1, 2024 | May 31, 2026 | HUGHES, CHRISTOPHER C. W. | reporter.nih.gov |
| PROSPECT: Pathways, Risk factors, and mOleculeS to Prevent Early-onset Colorectal Tumors | NIH | National Cancer Institute | 2024 to 2025 | $1,020,731 | May 1, 2024 | April 30, 2026 | BALSKUS, EMILY PATRICIA | reporter.nih.gov |
| The role of leukemia inhibitory factor in colorectal cancer | NIH | National Cancer Institute | 2023 to 2025 | $1,018,588 | February 1, 2022 | January 31, 2027 | HU, WENWEI | reporter.nih.gov |
| Mitochondrial bioenergetics and colorectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,018,451 | February 19, 2024 | May 31, 2029 | FISHER-WELLMAN, KELSEY H | reporter.nih.gov |
| The role of the mycobiome in cancer | NIH | National Cancer Institute | 2024 to 2025 | $1,017,386 | February 1, 2024 | January 31, 2029 | ILIEV, ILIYAN DIMITROV | reporter.nih.gov |
| A Phospholipid-Derived Nanotherapeutic Platform for Improved Colorectal Cancer Immunochemotherapy | NIH | National Cancer Institute | 2023 to 2025 | $1,016,541 | April 1, 2023 | March 31, 2028 | LU, JIANQIN | reporter.nih.gov |
| Enteric Glia is New Biological Target to Block Drug Resistance in Colon Cancer | NIH | National Cancer Institute | 2023 to 2025 | $993,191 | April 1, 2023 | March 31, 2028 | VAN LANDEGHEM, LAURIANNE CHANTAL | reporter.nih.gov |
| Assembly and function of outer membrane tubules in Fusobacterium nucleatum | NIH | National Institute of Dental & Craniofacial Research | 2024 to 2025 | $988,946 | May 1, 2024 | April 30, 2029 | TON-THAT, HUNG | reporter.nih.gov |
| Advancing top-down proteomics with capillary electrophoresis-mass spectrometry | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $983,629 | May 1, 2024 | April 30, 2029 | SUN, LIANGLIANG | reporter.nih.gov |
| Development of SUV39H1-selective inhibitor for human colon cancer therapy | NIH | National Cancer Institute | 2024 to 2025 | $982,509 | February 1, 2024 | January 31, 2029 | LIU, KEBIN | reporter.nih.gov |
| Mechanism and approach to inactivate mutant KRAS of lung metastatic colon cancer by RNA-ligand-displaying exosome to co-deliver dCas9--gRNA ribonucleoprotein complex and KRAS siRNA | NIH | National Cancer Institute | 2024 to 2025 | $972,447 | July 2, 2024 | June 30, 2026 | GUO, PEIXUAN | reporter.nih.gov |
| Harnessing treatment-induced tumor evolution and collateral sensitivities using a human rectal cancer co-clinical platform | NIH | National Cancer Institute | 2022 to 2025 | $962,266 | September 13, 2022 | August 31, 2027 | EYLER, CHRISTINE ELISSA | reporter.nih.gov |
| TLR Agonist Nano-Immune Therapy for Peritoneal Metastases | NIH | National Cancer Institute | 2024 to 2025 | $948,125 | September 9, 2024 | August 31, 2029 | SERDA, RITA ELENA | reporter.nih.gov |
| Research and mentoring program in shared decision making in the care of older adults | NIH | National Institute on Aging | 2021 to 2025 | $946,256 | April 1, 2021 | March 31, 2027 | SCHONBERG, MARA A | reporter.nih.gov |
| Targeting defective necroptosis in colorectal cancer | NIH | National Cancer Institute | 2023 to 2024 | $926,503 | December 1, 2019 | March 31, 2026 | ZHANG, LIN | reporter.nih.gov |
| Colon cell mechanoregulation through an E-cadherin - associated RNAi machinery | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 to 2025 | $926,351 | April 1, 2024 | March 31, 2028 | KOURTIDIS, ANTONIS | reporter.nih.gov |
| Mechanisms for environmental microplastics-enhanced colorectal tumor progression | NIH | National Institute of Environmental Health Sciences | 2024 to 2025 | $909,141 | August 16, 2024 | July 31, 2029 | XUE, XIANG | reporter.nih.gov |
| Building a Cancer Epidemiology Cohort to Investigate Factors Associated with Higher Risk of Colorectal Cancer among Alaska Native People | NIH | National Cancer Institute | 2024 to 2025 | $893,216 | August 1, 2024 | July 31, 2029 | REDWOOD, DIANA | reporter.nih.gov |
| Elucidating the impact of DNA hypomethylation on genome organization and anti-tumor transcriptional programs | NIH | National Cancer Institute | 2021 to 2025 | $888,619 | April 1, 2021 | March 31, 2027 | JOHNSTONE, SARAH E | reporter.nih.gov |
| Assessment of strategies for targeting transcriptional co-activators in colorectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $885,766 | August 15, 2024 | July 31, 2029 | FISHER, KURT | reporter.nih.gov |
| Biomarker discovery in colon cancer through next-generation metabolomics | NIH | National Cancer Institute | 2025 | $881,647 | September 2, 2025 | August 31, 2027 | STANCLIFFE, ETHAN | reporter.nih.gov |
| Validation of blood-based predictive biomarkers of therapeutic response to neoadjuvant chemoradiation therapy in patients with locally advanced rectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $870,915 | May 1, 2022 | April 30, 2027 | ARORA, SANJEEVANI | reporter.nih.gov |
| Targeting LSD1 to prevent therapy-induced transdifferentiation in BRAF mutant colorectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $866,472 | April 1, 2024 | March 31, 2029 | O'HAGAN, HEATHER M | reporter.nih.gov |
| Regulation of RBP Function during EMT | NIH | National Cancer Institute | 2024 to 2025 | $853,791 | May 1, 2024 | April 30, 2029 | LEWIS, ROBERT E. | reporter.nih.gov |
| Molecular Mechanisms of Fructose-induced Colorectal Cancer Cell Survival | NIH | National Cancer Institute | 2024 to 2025 | $845,322 | January 10, 2022 | December 31, 2026 | GONCALVES, MARCUS DASILVA | reporter.nih.gov |
| Type VII secretion in Streptococcus gallolyticus pathogenesis | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $842,340 | December 1, 2023 | October 31, 2028 | XU, YI | reporter.nih.gov |
| Improving Diagnosis in Gastrointestinal Cancer: Integrating Prediction Models into Routine Clinical Care | NIH | National Cancer Institute | 2023 to 2025 | $829,581 | July 1, 2023 | June 30, 2027 | READ, ANDREW J | reporter.nih.gov |
| Mutant p53 gain-of-function as an actionable target in cancer therapy | NIH | National Cancer Institute | 2021 to 2024 | $828,596 | September 11, 2020 | August 31, 2025 | NEMAJEROVA, ALICE | reporter.nih.gov |
| PROSPECT - Stem cell models | NIH | National Cancer Institute | 2024 to 2025 | $811,617 | May 1, 2024 | April 30, 2026 | YILMAZ, OMER | reporter.nih.gov |
| Fatty Acid Synthase as a Novel Molecular Target for Colon Cancer Treatment | NIH | National Cancer Institute | 2024 to 2025 | $805,936 | March 1, 2024 | February 28, 2029 | GAO, TIANYAN | reporter.nih.gov |
| Neoadjuvant Tucatinib plus Trastuzumab in HER2-amplified Locally Advanced Rectal Cancer | NIH | National Cancer Institute | 2024 to 2025 | $805,200 | March 1, 2024 | February 28, 2029 | CERCEK, ANDREA | reporter.nih.gov |
| Mechanisms of metabolic reprogramming by PIK3CA oncogenic mutations | NIH | National Cancer Institute | 2024 to 2025 | $805,000 | January 17, 2024 | December 31, 2028 | WANG, ZHENGHE | reporter.nih.gov |
| Physical activity intervention co-created and pilot tested with African American Colorectal Cancer Survivors | NIH | National Institute on Minority Health and Health Disparities | 2021 to 2025 | $795,103 | May 3, 2021 | January 31, 2026 | HIRSCHEY, RACHEL | reporter.nih.gov |
| Regulation and Localization of Mismatch Repair Proteins | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $794,650 | August 1, 2022 | May 31, 2027 | HAYE, JOANNA E | reporter.nih.gov |
| The Impact of HIV on the Tumor Microenviornment and Survival in Colorectal Cancer Patients in South Africa | NIH | National Cancer Institute | 2024 to 2025 | $779,156 | April 1, 2024 | March 31, 2029 | HERSHMAN, DAWN | reporter.nih.gov |
| Imaging nanoscale chromatin folding in early carcinogenesis | NIH | National Cancer Institute | 2023 to 2025 | $777,902 | August 1, 2020 | May 31, 2026 | LIU, YANG | reporter.nih.gov |
| A Targeted Approach to Treat Immunotherapy-Induced Myocarditis with CXCR3 Blockade | NIH | National Heart, Lung, and Blood Institute | 2025 | $773,843 | September 19, 2025 | May 31, 2029 | ZHU, HAN | reporter.nih.gov |
| Mechanistic and Pharmacokinetic Studies of Classical Chinese Formula Xiao Chai Hu Tang Against Irinotecan-Induced Gut Toxicities | NIH | National Cancer Institute | 2021 to 2024 | $769,859 | September 11, 2020 | June 30, 2025 | HU, MING | reporter.nih.gov |
| Exploiting Carbon Monoxide Biofoams to Radio-Sensitize Rectal Cancer Cells While Protecting Normal Bowel | NIH | National Cancer Institute | 2023 to 2025 | $756,848 | June 9, 2023 | May 31, 2028 | BYRNE, JAMES DONALD | reporter.nih.gov |
| Discovery of host genetic elements affecting response to immune checkpoint inhibitors | NIH | National Cancer Institute | 2025 | $754,511 | December 13, 2024 | November 30, 2029 | LIU, EDISON TAK-BUN | reporter.nih.gov |
| Leveraging artificial intelligence/machine learning-based technology to overcome specialized training and technology barriers for the diagnosis and prognostication of colorectal cancer in Africa | NIH | National Cancer Institute | 2023 to 2025 | $749,998 | September 15, 2023 | August 31, 2026 | SALEH, MANSOOR N | reporter.nih.gov |
| Novel radiomic signatures for treatment response to neoadjuvant therapy in rectal cancers | NIH | National Cancer Institute | 2024 to 2025 | $749,106 | May 15, 2024 | September 15, 2025 | VISWANATH, SATISH EASWAR | reporter.nih.gov |
| Genetics of Tumor Suppression by p53 | NIH | National Cancer Institute | 2022 to 2024 | $747,000 | March 4, 2020 | November 30, 2024 | BARNOUD, THIBAUT | reporter.nih.gov |
| Understanding methionine metabolism and its therapeutic potential in cancer | NIH | National Cancer Institute | 2022 to 2024 | $747,000 | April 1, 2022 | September 30, 2025 | GAO, XIA | reporter.nih.gov |
| Elucidating the Role of SMAD4 in Colorectal Cancer | NIH | National Cancer Institute | 2022 to 2024 | $747,000 | July 1, 2022 | June 30, 2026 | TONG, KEVIN | reporter.nih.gov |
| Targeting the IL-33/ST2 Pathway in Colorectal Cancer Immunotherapy | NIH | National Cancer Institute | 2023 to 2025 | $747,000 | February 1, 2023 | January 31, 2026 | VAN DER JEUGHT, KEVIN | reporter.nih.gov |
| Functional characterization of novel oncogenic loci driving progression and immune response in gastrointestinal cancer | NIH | National Cancer Institute | 2023 to 2025 | $747,000 | September 1, 2021 | August 31, 2026 | LO, YUAN-HUNG | reporter.nih.gov |
| Developing multiplexed microenvironmental sensors for precision diagnostics of cancer metastasis | NIH | National Cancer Institute | 2023 to 2025 | $747,000 | January 1, 2020 | February 28, 2026 | HAO, LIANGLIANG | reporter.nih.gov |
| InSiGHT-ClinGen Polyposis/Colon Cancer Variant Curation Expert Panel | NIH | National Cancer Institute | 2021 to 2024 | $745,538 | June 10, 2021 | May 31, 2026 | GREENBLATT, MARC S | reporter.nih.gov |
| Characterization of polyamine biosynthetic enzymes from human gut microbes associated with colon and pancreatic cancer | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $744,530 | July 15, 2022 | June 30, 2027 | MCFARLANE, JEFFREY S | reporter.nih.gov |
| Exploring the impact of HSP90 inhibition on antigen presentation and anti-tumor immune responses | NIH | National Cancer Institute | 2022 to 2024 | $742,016 | March 2, 2020 | February 28, 2025 | JAEGER, ALEX | reporter.nih.gov |
| Role of lncRNA UCA1 in anoikis resistantce and colorectal cancer metastasis | NIH | National Institute of General Medical Sciences | 2022 to 2025 | $740,000 | September 1, 2022 | July 31, 2027 | TRIPATHI, MANISH K | reporter.nih.gov |
| Role of LRG1 in colorectal cancer tumorigenesis | NIH | National Cancer Institute | 2024 to 2025 | $736,576 | February 1, 2024 | January 31, 2029 | WANG, RUI | reporter.nih.gov |
| Polyunsaturated fatty acids and colorectal tumor risk: a molecular and genetic epidemiology study | NIH | National Cancer Institute | 2021 to 2024 | $736,512 | February 1, 2021 | July 31, 2025 | KHANKARI, NIKHIL KISHOR | reporter.nih.gov |
| Illuminating the evolutionary history of colorectal cancer metastasis: basic principles and clinical applications | NIH | National Cancer Institute | 2023 to 2024 | $735,681 | September 1, 2023 | May 14, 2025 | NAXEROVA, KAMILA | reporter.nih.gov |
| Leveraging Radiation-Induced Senescence and PTPN2 Inhibition to Enhance Immune-Mediated Tumor Control in Rectal Cancer | NIH | National Cancer Institute | 2025 | $730,398 | September 1, 2025 | August 31, 2030 | ROMESSER, PAUL BERNARD | reporter.nih.gov |
| Engineered probiotic bacteria for colorectal cancer immunoprevention and interception | NIH | National Cancer Institute | 2025 | $727,904 | August 11, 2025 | May 31, 2027 | ARPAIA, NICHOLAS | reporter.nih.gov |
| Persistent Poverty and Colorectal Cancer Risk: Elucidating biological, behavioral, and place-based pathways | NIH | National Cancer Institute | 2025 | $724,840 | August 21, 2025 | July 31, 2030 | CHENG, IONA C | reporter.nih.gov |
| Increasing CRC Screening in Community Health Centers through Mobile Messaging Optimization | NIH | National Cancer Institute | 2025 | $724,556 | August 1, 2025 | July 31, 2030 | KRUSE, GINA RAE | reporter.nih.gov |
| Dissecting roles of microbiome-host interactions in colorectal neoplasia etiology using multi-omics data | NIH | National Cancer Institute | 2023 to 2025 | $723,990 | January 5, 2021 | March 31, 2027 | YANG, YAOHUA | reporter.nih.gov |
| Chemical synthesis to access rare heterocycles and tool compounds to probe bacterial polysaccharide metabolism | NIH | National Institute of General Medical Sciences | 2024 to 2025 | $721,207 | September 1, 2024 | June 30, 2029 | WHITEHEAD, DANIEL CHARLES | reporter.nih.gov |
| Automated Multi-Timepoint CT Analysis for Enhanced Metastatic Disease Evaluation in Colorectal Cancer: An Anatomy-Aware Vision-Language AI Approach | NIH | National Institute of Biomedical Imaging and Bioengineering | 2025 | $718,456 | July 1, 2025 | May 31, 2029 | WANG, KANG | reporter.nih.gov |
| The Meharry Cancer Summer Research Program (SuRP) | NIH | National Cancer Institute | 2023 to 2025 | $717,582 | September 1, 2023 | August 31, 2028 | STEWART, LAMONICA VANETTE | reporter.nih.gov |
| Addressing cancer disparities in Nigeria through Immuno-oncology Research – The NOLA Program | NIH | National Cancer Institute | 2024 to 2025 | $716,532 | September 16, 2024 | August 31, 2026 | KINGHAM, T PETER | reporter.nih.gov |
| T helper cells and stem cells in colon homeostasis and tumor initiation | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $715,501 | March 15, 2025 | January 31, 2030 | HAN, ARNOLD | reporter.nih.gov |
| Redefining indications of EGFR inhibitors in cancers that harbor mutant RAS | NIH | National Cancer Institute | 2024 to 2025 | $713,700 | September 1, 2024 | August 31, 2029 | MCFALL, THOMAS BRADLEY | reporter.nih.gov |
| The regulation of gut macrophage’s function by the bile acid receptor FXR | NIH | National Cancer Institute | 2024 to 2025 | $711,412 | May 1, 2024 | April 30, 2029 | FU, TING | reporter.nih.gov |
| A spatial profiling-based immune hub perturbation platform to improve immunotherapy in colon cancer | NIH | National Cancer Institute | 2025 | $710,361 | August 1, 2025 | May 31, 2030 | PELKA, KARIN | reporter.nih.gov |
| Prebiotic effect of eicosapentaenoic acid treatment for colorectal cancer livermetastasis | NIH | National Cancer Institute | 2024 | $710,138 | July 1, 2024 | May 19, 2025 | GARRETT, WENDY S. | reporter.nih.gov |
| Dissecting the in vivo stromal metabolic and inflammatory crosstalk in colorectal cancer | NIH | National Cancer Institute | 2022 to 2025 | $701,144 | August 16, 2022 | July 31, 2027 | DURAN MOLINA, MARIA ANGELES | reporter.nih.gov |
| Deciphering the Critical Determinants of Enteric and Tumor Niche Colonization by Microbes in Colorectal Cancer | NIH | National Cancer Institute | 2025 | $697,763 | February 1, 2025 | January 31, 2030 | JOHNSTON, CHRISTOPHER D | reporter.nih.gov |
| Exercise as Interception Therapy in Primary High Risk Cancer | NIH | National Cancer Institute | 2025 | $693,662 | September 3, 2020 | June 30, 2027 | JONES, LEE W | reporter.nih.gov |
| A non-invasive blood test for multi-cancer detection and determination of tissue of origin preceding overt cancer diagnosis | NIH | National Cancer Institute | 2025 | $692,491 | May 1, 2025 | April 30, 2030 | BISSONNETTE, BRUCE MARC | reporter.nih.gov |
| Role and Regulation of Asparagine in Colorectal Cancer | NIH | National Cancer Institute | 2025 | $688,092 | January 1, 2025 | December 31, 2029 | JOHNSON, CAROLINE HELEN | reporter.nih.gov |
| Adaptive Randomization of Aerobic Exercise During Chemotherapy in Colon Cancer | NIH | National Cancer Institute | 2024 to 2025 | $675,764 | June 3, 2022 | May 31, 2028 | BROWN, JUSTIN C | reporter.nih.gov |
| Addressing Colorectal Cancer-Related Distress: Developing and Evaluating a Couple-Based Mindfulness Intervention | NIH | National Cancer Institute | 2022 to 2025 | $672,640 | August 12, 2022 | August 31, 2027 | ZIMMARO, LAUREN A. | reporter.nih.gov |
| Optical hyperspectral nanoscale chromatin analysis for colon cancer risk-stratification | NIH | National Cancer Institute | 2025 | $670,534 | May 1, 2025 | April 30, 2030 | BACKMAN, VADIM | reporter.nih.gov |
| A Systems Theory Approach to the Study of Colon and Lung Cancer Survivorship Using Novel Data Linkages | NIH | National Cancer Institute | 2024 to 2025 | $669,183 | September 16, 2024 | August 31, 2029 | ADAMS, SWANN ARP | reporter.nih.gov |
| Regulatory role for an epithelial repair protein, LINGO2, in colitis | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $667,440 | July 1, 2020 | March 31, 2025 | BELLE, NICOLE MALONEY | reporter.nih.gov |
| Discovery and verification of methylated circulating tumor DNA markers for the detection of colorectal cancer in subjects under 50 years of age | NIH | National Cancer Institute | 2025 | $663,923 | July 1, 2021 | June 30, 2027 | HITCHINS, MEGAN P | reporter.nih.gov |
| Tumor-Selective Radiosensitization by Targeting Hypoxia in Rectal Cancer | NIH | National Cancer Institute | 2025 | $662,096 | February 1, 2025 | January 31, 2030 | WILLIAMS, TERENCE MARQUES | reporter.nih.gov |
| Adaptive imaging for pioneering multiplexed spatial profiling of tumors and tissues for cancer research and diagnosis | NIH | National Cancer Institute | 2025 | $658,336 | June 1, 2025 | May 31, 2028 | GEORGE, TAD | reporter.nih.gov |
| Metabolic reprogramming to boost the fitness of anti-tumor immunity against metastatic colon cancer | NIH | National Cancer Institute | 2025 | $640,583 | April 1, 2025 | March 31, 2030 | BEYAZ, SEMIR | reporter.nih.gov |
| Interventions to Decrease Cancer Information Avoidance | NIH | National Cancer Institute | 2025 | $637,596 | April 4, 2025 | March 31, 2030 | OROM, HEATHER | reporter.nih.gov |
| A community-engaged intervention to increase colorectal cancer screening in communities with suboptimal screening | NIH | National Cancer Institute | 2022 to 2025 | $635,025 | September 14, 2022 | August 31, 2027 | VANG, SUZANNE SHARRY | reporter.nih.gov |
| Impact of Aspirin on the Gut Microbiome and Mucosal Microenvironment | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2021 to 2024 | $632,880 | February 6, 2020 | February 28, 2025 | DREW, DAVID A | reporter.nih.gov |
| Targeting a human gut bacterial genotoxin via engineered commensal bacteria | NIH | National Cancer Institute | 2025 | $627,422 | May 1, 2025 | April 30, 2030 | LI, JIAHE | reporter.nih.gov |
| Improving colorectal cancer screening decisions through consideration of life expectancy | NIH | National Institute on Aging | 2025 | $625,452 | January 1, 2025 | December 31, 2029 | MARTINEZ, KATHRYN ANNE | reporter.nih.gov |
| Influence of developmental programming in adult stem cells and cancer | NIH | National Cancer Institute | 2025 | $621,570 | August 8, 2025 | July 31, 2030 | MANA, MIYEKO | reporter.nih.gov |
| PROACT: Promoting Follow-up of Abnormal Colorectal Cancer Screening Tests through Multilevel Interventions | NIH | National Cancer Institute | 2025 | $621,406 | August 1, 2025 | July 31, 2030 | ISSAKA, RACHEL B. | reporter.nih.gov |
| 3D Engineered Model of Microscopic Colorectal Cancer Liver Metastasis for Adjuvant Chemotherapy Screens | NIH | National Cancer Institute | 2023 to 2025 | $620,295 | January 1, 2023 | December 31, 2028 | RAGHAVAN, SHREYA A. | reporter.nih.gov |
| The Role of Prohibitin 1 in Ethanol's Sensitizing Effect on Colorectal Liver Metastasis | NIH | National Institute on Alcohol Abuse and Alcoholism | 2025 | $617,748 | September 10, 2025 | June 30, 2030 | LU, SHELLY CHI-LOO | reporter.nih.gov |
| Discovery and Development of Natural Products for Interception of CRC | NIH | National Cancer Institute | 2024 to 2025 | $607,750 | May 14, 2024 | April 30, 2027 | RAO, CHINTHALAPALLY V. | reporter.nih.gov |
| Metabolic modulation of Fusobacterium nucleatum virulence | NIH | National Institute of Dental & Craniofacial Research | 2023 to 2024 | $604,857 | March 1, 2023 | February 28, 2026 | TON-THAT, HUNG | reporter.nih.gov |
| Mechanisms and strategies to rescue suboptimal T cell priming in colon cancer | NIH | National Cancer Institute | 2023 to 2025 | $603,126 | September 1, 2023 | August 31, 2026 | WESTCOTT, PETER MAXWELL KIENITZ | reporter.nih.gov |
| Decoding the functional pleiotropy of IL-20Rβ ligands in inflammation and tumorigenesis | NIH | National Cancer Institute | 2023 to 2025 | $600,696 | February 20, 2023 | January 31, 2026 | SAXTON, ROBERT ANDREW | reporter.nih.gov |
| Microbial and host biomarkers in colorectal cancer oncogenesis | NIH | National Cancer Institute | 2025 | $600,499 | April 1, 2025 | March 31, 2030 | HAN, YIPING | reporter.nih.gov |
| Chimeric RNA driven neopeptide vaccine for prevention of breast cancer in germline BRCA1/2 carriers | NIH | National Cancer Institute | 2025 | $597,289 | July 9, 2025 | June 30, 2027 | BEDROSIAN, ISABELLE | reporter.nih.gov |
| Computational approaches to the mechanistic elucidation of the serrated pathway of human colon carcinogenesis | NIH | National Cancer Institute | 2023 to 2025 | $596,163 | August 1, 2023 | July 31, 2028 | MOUSSA, MARMAR | reporter.nih.gov |
| A Novel Nanodrug for Metabolic Disease Treatment | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2024 | $594,547 | September 2, 2024 | August 31, 2025 | WAN, YU-JUI YVONNE | reporter.nih.gov |
| Engineering ingestible nanosensors for breath-based detection of colorectal cancer | NIH | National Cancer Institute | 2025 | $592,866 | March 15, 2025 | February 28, 2030 | CHAN, LESLIE | reporter.nih.gov |
| Optimization of an active mutant KRAS peptide vaccine in colorectal cancer | NIH | National Cancer Institute | 2025 | $589,838 | January 10, 2025 | December 31, 2029 | AZAD, NILOFER S. | reporter.nih.gov |
| 3D Printed Engineered Living Materials for Drug Delivery | NIH | National Institute of Biomedical Imaging and Bioengineering | 2022 to 2024 | $588,952 | April 5, 2022 | December 31, 2025 | NELSON, ALSHAKIM | reporter.nih.gov |
| Differential Wnt Dependencies in Colon Epithelium. | NIH | National Cancer Institute | 2023 to 2025 | $588,612 | September 1, 2023 | August 31, 2028 | ENG, GEORGE | reporter.nih.gov |
| Targeting regenerative reprogramming in colorectal cancer | NIH | National Cancer Institute | 2024 to 2025 | $585,188 | September 1, 2024 | August 31, 2028 | ALONSO MARTINEZ, SALVADOR | reporter.nih.gov |
| Administrative Supplement: Autophagy mediated immune stimulation by reovirus in KRAS mutated colorectal cancer | NIH | National Cancer Institute | 2022 to 2024 | $578,463 | January 14, 2022 | December 31, 2024 | MAITRA, RADHASHREE | reporter.nih.gov |
| Let's Talk: Overcoming barriers to the uptake of cascade screening through a stakeholder-informed online intervention | NIH | National Human Genome Research Institute | 2024 | $575,098 | September 20, 2024 | August 31, 2026 | ROBERTS, MEGAN C. | reporter.nih.gov |
| Assessing feasibility of gastric cancer screening in the US | NIH | National Cancer Institute | 2025 | $564,414 | April 1, 2025 | March 31, 2030 | KIM, MICHELLE KANG | reporter.nih.gov |
| Immune control of oncogene selection in preneoplastic colon | NIH | National Cancer Institute | 2023 to 2025 | $555,942 | September 14, 2023 | August 31, 2028 | MIRZA, HARIS | reporter.nih.gov |
| Bundled Multicancer Screening and Genetic Services Navigation to Improve Cancer Outcomes | NIH | National Cancer Institute | 2025 | $547,047 | May 1, 2025 | April 30, 2030 | O'NEILL, SUZANNE C. | reporter.nih.gov |
| Targeting iRhom to Improve Colon Cancer Immunochemotherapy | NIH | National Cancer Institute | 2025 | $546,625 | January 9, 2025 | December 31, 2029 | LI, SONG | reporter.nih.gov |
| Functional Consequences of Racially Associated Ephrin Alterations on the Prostate Tumor Microenvironment | NIH | National Cancer Institute | 2022 to 2024 | $538,243 | July 3, 2019 | June 30, 2025 | FRANCO CORONEL, OMAR | reporter.nih.gov |
| Role of innate immunity and the microbiome in colitis associated dysplasia | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2025 | $536,536 | September 1, 2014 | April 30, 2027 | ABREU, MARIA TERESA | reporter.nih.gov |
| Interaction between dietary taurine and microbiota sulfur metabolism in the development of colorectal cancer | NIH | National Cancer Institute | 2025 | $536,489 | January 1, 2025 | December 31, 2029 | JOBIN, CHRISTIAN | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Sloan-Kettering Inst Can Research | New York, NY | 21 | $41.4 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 22 | $38.2 million | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 5 | $33.2 million | 0 | $0 |
| University of TX MD Anderson Can CTR | Houston, TX | 19 | $31.6 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 13 | $29.9 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 12 | $28.2 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 16 | $27 million | 0 | $0 |
| Univ of North Carolina Chapel Hill | Chapel Hill, NC | 13 | $25.9 million | 0 | $0 |
| Fred Hutchinson Cancer Center | Seattle, WA | 12 | $25.1 million | 0 | $0 |
| Cold Spring Harbor Laboratory | Cold Spring Harbor, NY | 3 | $23.9 million | 0 | $0 |
| Stanford University | Stanford, CA | 14 | $22 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 14 | $20.4 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 11 | $20.3 million | 0 | $0 |
| Ohio State University | Columbus, OH | 12 | $20.2 million | 0 | $0 |
| Cedars-Sinai Medical Center | Los Angeles, CA | 10 | $18.9 million | 0 | $0 |
| Ut Southwestern Medical Center | Dallas, TX | 11 | $17.3 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 10 | $16.7 million | 0 | $0 |
| University of Chicago | Chicago, IL | 15 | $15.8 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 12 | $15.6 million | 0 | $0 |
| Washington University | Saint Louis, MO | 11 | $15.3 million | 0 | $0 |
| Boston University Medical Campus | Boston, MA | 3 | $14.9 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 7 | $14.7 million | 0 | $0 |
| Harvard University D/b/a Harvard School of Public Health | Boston, MA | 12 | $14 million | 0 | $0 |
| Yale University | New Haven, CT | 10 | $13.3 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 6 | $12.7 million | 0 | $0 |
| Indiana University Indianapolis | Indianapolis, IN | 7 | $11 million | 0 | $0 |
| Beckman Research Institute/city of Hope | Duarte, CA | 6 | $10.9 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 5 | $10 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 5 | $9.9 million | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 6 | $9.9 million | 0 | $0 |
| University of Arizona | Tucson, AZ | 8 | $9.9 million | 0 | $0 |
| Research Inst of Fox Chase Can CTR | Philadelphia, PA | 4 | $9.6 million | 0 | $0 |
| Kaiser Foundation Research Institute | Oakland, CA | 4 | $9.6 million | 0 | $0 |
| University of California Los Angeles | Los Angeles, CA | 6 | $9.1 million | 0 | $0 |
| Case Western Reserve University | Cleveland, OH | 8 | $9.1 million | 0 | $0 |
| University of Melbourne | Melbourne | 1 | $9 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 9 | $8.9 million | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 4 | $8.9 million | 0 | $0 |
| Cleveland Clinic Lerner Com-Cwru | Cleveland, OH | 6 | $8.7 million | 0 | $0 |
| University of Washington | Seattle, WA | 7 | $8.7 million | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 4 | $8.4 million | 0 | $0 |
| University of Connecticut SCH of Med/dnt | Farmington, CT | 4 | $8.3 million | 0 | $0 |
| Emory University | Atlanta, GA | 5 | $8.2 million | 0 | $0 |
| Dana-Farber Cancer Inst | Boston, MA | 9 | $8.2 million | 0 | $0 |
| University of Illinois at Chicago | Chicago, IL | 4 | $8 million | 0 | $0 |
| University of Kentucky | Lexington, KY | 7 | $8 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 3 | $7.8 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 5 | $7.7 million | 0 | $0 |
| SUNY at Buffalo | Amherst, NY | 2 | $7.5 million | 0 | $0 |
| University of Nebraska Medical Center | Omaha, NE | 6 | $7.4 million | 0 | $0 |
| H. Lee Moffitt Cancer CTR & Res Inst | Tampa, FL | 5 | $7.3 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 7 | $7.2 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 7 | $7.1 million | 0 | $0 |
| University of South Carolina at Columbia | Columbia, SC | 6 | $7 million | 0 | $0 |
| ST. Jude Children's Research Hospital | Memphis, TN | 2 | $6.5 million | 0 | $0 |
| Harvard Medical School | Boston, MA | 7 | $6.2 million | 0 | $0 |
| University of California-Irvine | Irvine, CA | 5 | $6 million | 0 | $0 |
| University of Wisconsin-Madison | Madison, WI | 3 | $5.8 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 5 | $5.4 million | 0 | $0 |
| Vanderbilt University | Nashville, TN | 3 | $5.3 million | 0 | $0 |
| Medical University of South Carolina | Charleston, SC | 6 | $5.2 million | 0 | $0 |
| Mayo Clinic Arizona | Scottsdale, AZ | 2 | $5 million | 0 | $0 |
| Georgetown University | Washington, DC | 3 | $4.8 million | 0 | $0 |
| LSU Pennington Biomedical Research CTR | Baton Rouge, LA | 2 | $4.8 million | 0 | $0 |
| Westat, Inc. | Bethesda, MD | 1 | $4.5 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 4 | $4.4 million | 0 | $0 |
| University of Iowa | Iowa City, IA | 2 | $4.3 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 4 | $4.3 million | 0 | $0 |
| Albert Einstein College of Medicine | Bronx, NY | 4 | $4.2 million | 0 | $0 |
| Baylor College of Medicine | Houston, TX | 3 | $4.2 million | 0 | $0 |
| Therapyx, Inc. | Buffalo, NY | 1 | $4 million | 0 | $0 |
| Pennsylvania State Univ University Park | University Park, PA | 3 | $3.9 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 4 | $3.8 million | 0 | $0 |
| Columbus Community Clinical Oncology PRG | Columbus, OH | 1 | $3.8 million | 0 | $0 |
| Roswell Park Cancer Institute Corp | Buffalo, NY | 2 | $3.7 million | 0 | $0 |
| University of Illinois at Urbana-Champaign | Urbana, IL | 3 | $3.5 million | 0 | $0 |
| Stingray Therapeutics, Inc. | Houston, TX | 1 | $3.5 million | 0 | $0 |
| Harvard University | Cambridge, MA | 5 | $3.4 million | 0 | $0 |
| University of Hawaii | Honolulu, HI | 2 | $3.4 million | 0 | $0 |
| Columbia University | New York, NY | 2 | $3.4 million | 0 | $0 |
| Temple Univ of the Commonwealth | Philadelphia, PA | 3 | $3.3 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 2 | $3.3 million | 0 | $0 |
| Michigan State University | East Lansing, MI | 3 | $3.3 million | 0 | $0 |
| Virginia Commonwealth University | Richmond, VA | 4 | $3.2 million | 0 | $0 |
| Actuated Medical, Inc. | Bellefonte, PA | 1 | $3.2 million | 0 | $0 |
| Wayne State University | Detroit, MI | 1 | $3 million | 0 | $0 |
| BCN Biosciences, LLC | Pasadena, CA | 1 | $3 million | 0 | $0 |
| Texas A&m University Health Science CTR | College Station, TX | 3 | $3 million | 0 | $0 |
| Averto Medical INC | Fremont, CA | 2 | $3 million | 0 | $0 |
| University of Florida | Gainesville, FL | 3 | $2.9 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 5 | $2.9 million | 0 | $0 |
| Rockefeller University | New York, NY | 3 | $2.8 million | 0 | $0 |
| Augusta University | Augusta, GA | 3 | $2.7 million | 0 | $0 |
| University of Texas HLTH Sci CTR Houston | Houston, TX | 4 | $2.6 million | 0 | $0 |
| Louisiana State Univ HSC Shreveport | Shreveport, LA | 3 | $2.5 million | 0 | $0 |
| Morehouse School of Medicine | Atlanta, GA | 2 | $2.4 million | 0 | $0 |
| Duke University | Durham, NC | 2 | $2.4 million | 0 | $0 |
| Bobcatbio, Inc. | Hummelstown, PA | 1 | $2.4 million | 0 | $0 |
| Deep Creek Pharma, LLC | Yadkinville, NC | 2 | $2.4 million | 0 | $0 |
| Digital Health Navigation Solutions, LLC | Winston Salem, NC | 1 | $2.4 million | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 528 | $286,750,191 | 0 | $0 |
| 2024 | 569 | $275,131,208 | 0 | $0 |
| 2023 | 423 | $226,617,338 | 0 | $0 |
| 2022 | 296 | $167,947,515 | 0 | $0 |
| 2021 | 202 | $120,703,185 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.